BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4. [PMID: 1348364 DOI: 10.1073/pnas.89.7.3070] [Cited by in Crossref: 604] [Cited by in F6Publishing: 603] [Article Influence: 20.8] [Reference Citation Analysis]
Number Citing Articles
1 López-Lázaro M. Selective amino acid restriction therapy (SAART): a non-pharmacological strategy against all types of cancer cells. Oncoscience 2015;2:857-66. [PMID: 26682277 DOI: 10.18632/oncoscience.258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Bozkaya Y, Yazıcı O. Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer. Expert Rev Mol Diagn 2019;19:267-72. [PMID: 30722710 DOI: 10.1080/14737159.2019.1579644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Liang X, Shen D, Gottesman MM. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry 2004;98:1599-606. [DOI: 10.1016/j.jinorgbio.2004.05.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
4 Tomonari A, Nishio K, Kurokawa H, Arioka H, Ishida T, Fukumoto H, Fukuoka K, Nomoto T, Iwamoto Y, Heike Y, Itakura M, Saijo N. Identification of cis-acting DNA elements of the human gamma-glutamylcysteine synthetase heavy subunit gene. Biochem Biophys Res Commun 1997;232:522-7. [PMID: 9125214 DOI: 10.1006/bbrc.1997.6319] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
5 Sethi G, Kwon Y, Burkhalter RJ, Pathak HB, Madan R, McHugh S, Atay S, Murthy S, Tawfik OW, Godwin AK. PTN signaling: Components and mechanistic insights in human ovarian cancer. Mol Carcinog 2015;54:1772-85. [PMID: 25418856 DOI: 10.1002/mc.22249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
6 Schumann C, Chan S, Khalimonchuk O, Khal S, Moskal V, Shah V, Alani AW, Taratula O, Taratula O. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer. Mol Pharm 2016;13:2070-83. [PMID: 27170529 DOI: 10.1021/acs.molpharmaceut.6b00205] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
7 Brozovic A, Ambriović-Ristov A, Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 2010;40:347-59. [PMID: 20163198 DOI: 10.3109/10408441003601836] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 11.3] [Reference Citation Analysis]
8 Tastesen HS, Holm JB, Møller J, Poulsen KA, Møller C, Stürup S, Hoffmann EK, Lambert IH. Pinpointing differences in cisplatin-induced apoptosis in adherent and non-adherent cancer cells. Cell Physiol Biochem 2010;26:809-20. [PMID: 21220912 DOI: 10.1159/000323990] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
9 Mulders TMT, Keizer J, Breimer DD, Mulder GJ. In Vivo Characterization and Modulation of the Glutathione/Glutathione S- Transferase System in Cancer Patients. Drug Metabolism Reviews 2008;27:191-229. [DOI: 10.3109/03602539509029823] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
10 Kinnula K, Linnainmaa K, Raivio KO, Kinnula VL. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer 1998;77:1097-102. [PMID: 9569045 DOI: 10.1038/bjc.1998.182] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
11 da Silva Machado C, Mendonça LM, Venancio VDP, Bianchi MLP, Antunes LMG. Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity. NeuroToxicology 2013;36:10-6. [DOI: 10.1016/j.neuro.2013.02.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
12 Harper BW, Morris TT, Gailer J, Aldrich-wright JR. Probing the interaction of bisintercalating (2,2′:6′,2″-terpyridine)platinum(II) complexes with glutathione and rabbit plasma. Journal of Inorganic Biochemistry 2016;163:95-102. [DOI: 10.1016/j.jinorgbio.2016.06.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
13 O’dwyer PJ, Hamilton TC, Yao K, Tew KD, Ozols RF. Modulation of Glutathione and Related Enzymes in Reversal of Resistance to Anticancer Drugs. Hematology/Oncology Clinics of North America 1995;9:383-96. [DOI: 10.1016/s0889-8588(18)30100-x] [Cited by in Crossref: 16] [Article Influence: 0.6] [Reference Citation Analysis]
14 Gutiérrez AG, Vázquez-Aguirre A, García-Ramos JC, Flores-Alamo M, Hernández-Lemus E, Ruiz-Azuara L, Mejía C. Copper(II) mixed chelate compounds induce apoptosis through reactive oxygen species in neuroblastoma cell line CHP-212. J Inorg Biochem 2013;126:17-25. [PMID: 23727332 DOI: 10.1016/j.jinorgbio.2013.05.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
15 Sagara Y, Dargusch R, Chambers D, Davis J, Schubert D, Maher P. Cellular mechanisms of resistance to chronic oxidative stress. Free Radic Biol Med 1998;24:1375-89. [PMID: 9641255 DOI: 10.1016/s0891-5849(97)00457-7] [Cited by in Crossref: 113] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
16 Guo S, Liu M, Godwin AK. Transcriptional regulation of hTREX84 in human cancer cells. PLoS One 2012;7:e43610. [PMID: 22952718 DOI: 10.1371/journal.pone.0043610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun 2017;8:2166. [PMID: 29255160 DOI: 10.1038/s41467-017-02390-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
18 Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 2016;106:27-36. [PMID: 26804248 DOI: 10.1016/j.phrs.2016.01.001] [Cited by in Crossref: 224] [Cited by in F6Publishing: 219] [Article Influence: 44.8] [Reference Citation Analysis]
19 Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rusmussen AA, Montogomery EA, Bischoff EK, Hanigan MH, Cullen KJ. Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chemico-Biological Interactions 1998;111-112:187-98. [DOI: 10.1016/s0009-2797(97)00161-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
20 Saha A, Devi PS. Surface Functionalized Multifunctional Gd 2 O 3 –Fluorescein Composite Nanorods for Redox Responsive Drug Delivery and Imaging Applications. ACS Appl Nano Mater 2018;1:2898-911. [DOI: 10.1021/acsanm.8b00535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Cortes-Wanstreet MM, Giedzinski E, Limoli CL, Luderer U. Overexpression of glutamate-cysteine ligase protects human COV434 granulosa tumour cells against oxidative and gamma-radiation-induced cell death. Mutagenesis 2009;24:211-24. [PMID: 19153097 DOI: 10.1093/mutage/gen073] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
22 Yuan Z, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1. Journal of Biological Chemistry 2003;278:23432-40. [DOI: 10.1074/jbc.m302674200] [Cited by in Crossref: 154] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
23 Santos I, Ramos C, Mendes C, Sequeira CO, Tomé CS, Fernandes DGH, Mota P, Pires RF, Urso D, Hipólito A, Antunes AMM, Vicente JB, Pereira SA, Bonifácio VDB, Nunes SC, Serpa J. Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation. Nutrients 2019;11:E2523. [PMID: 31635026 DOI: 10.3390/nu11102523] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
24 Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008;7:3247-55. [PMID: 18852128 DOI: 10.1158/1535-7163.MCT-08-0250] [Cited by in Crossref: 64] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
25 Yang X, Pan Z, Choudhury MR, Yuan Z, Anifowose A, Yu B, Wang W, Wang B. Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery. Med Res Rev 2020;40:2682-713. [PMID: 32803765 DOI: 10.1002/med.21720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Choi M, Kim D. Platinum transporters and drug resistance. Arch Pharm Res 2006;29:1067-73. [DOI: 10.1007/bf02969293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
27 Goto S, Ihara Y, Urata Y, Izumi S, Abe K, Koji T, Kondo T. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J. 2001;15:2702-2714. [PMID: 11726546 DOI: 10.1096/fj.01-0376com] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
28 Auner GW, Koya SK, Huang C, Broadbent B, Trexler M, Auner Z, Elias A, Mehne KC, Brusatori MA. Applications of Raman spectroscopy in cancer diagnosis. Cancer Metastasis Rev 2018;37:691-717. [PMID: 30569241 DOI: 10.1007/s10555-018-9770-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
29 Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F, Hu W, Yuan Z, Nie C, Wei Y. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J. 2012;444:291-301. [PMID: 22394200 DOI: 10.1042/BJ20111855] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
30 Păunescu E, Soudani M, Martin P, Scopelliti R, Lo Bello M, Dyson PJ. Organometallic Glutathione S -Transferase Inhibitors. Organometallics 2017;36:3313-21. [DOI: 10.1021/acs.organomet.7b00468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
31 Bergman A, Giaccone G, van Moorsel C, Mauritz R, Noordhuis P, Pinedo H, Peters G. Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. European Journal of Cancer 2000;36:1974-83. [DOI: 10.1016/s0959-8049(00)00246-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
32 Iantomasi T, Favilli F, Degl’innocenti D, Vincenzini MT. Increased glutathione synthesis associated with platelet-derived growth factor stimulation of NIH3T3 fibroblasts. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1999;1452:303-12. [DOI: 10.1016/s0167-4889(99)00142-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 David-West G, Ernlund A, Gadi A, Schneider RJ. mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs. Oncotarget 2018;9:33064-76. [PMID: 30237852 DOI: 10.18632/oncotarget.25869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
34 Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103-141. [PMID: 24974180 DOI: 10.1016/b978-0-12-420117-0.00003-7] [Cited by in Crossref: 114] [Cited by in F6Publishing: 68] [Article Influence: 19.0] [Reference Citation Analysis]
35 Xiong Y, Xiao C, Li Z, Yang X. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem Soc Rev 2021;50:6013-41. [PMID: 34027953 DOI: 10.1039/d0cs00718h] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
36 Huang HL, Chao MW, Li YC, Chang LH, Chen CH, Chen MC, Cheng CC, Liou JP, Teng CM, Pan SL. MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer. Sci Rep 2016;6:31664. [PMID: 27526962 DOI: 10.1038/srep31664] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
37 Bosco C, Wulaningsih W, Melvin J, Santaolalla A, De Piano M, Arthur R, Van Hemelrijck M. Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalscience 2015;9:555. [PMID: 26284119 DOI: 10.3332/ecancer.2015.555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
38 See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: Current status and future prospects. Int J Gynecol Cancer 2003;13:701-34. [DOI: 10.1111/j.1525-1438.2003.13601.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
39 Salatino A, Aversa I, Battaglia AM, Sacco A, Di Vito A, Santamaria G, Chirillo R, Veltri P, Tradigo G, Di Cello A, Venturella R, Biamonte F, Costanzo F. H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS. Oxid Med Cell Longev 2019;2019:3461251. [PMID: 31781333 DOI: 10.1155/2019/3461251] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
40 Bansal A, Sanchez DJ, Nimgaonkar V, Sanchez D, Riscal R, Skuli N, Simon MC. Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression. Mol Cancer Res 2019;17:1881-92. [PMID: 31151999 DOI: 10.1158/1541-7786.MCR-18-1204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
41 Tang X, Wu J, Ding CK, Lu M, Keenan MM, Lin CC, Lin CA, Wang CC, George D, Hsu DS, Chi JT. Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. Cancer Res 2016;76:1892-903. [PMID: 26833124 DOI: 10.1158/0008-5472.CAN-15-2328] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
42 Sharawy N, Rashed L, Youakim MF. Evaluation of multi-neuroprotective effects of erythropoietin using cisplatin induced peripheral neurotoxicity model. Exp Toxicol Pathol 2015;67:315-22. [PMID: 25758589 DOI: 10.1016/j.etp.2015.02.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
43 Duan G, Shi M, Xie L, Xu M, Wang Y, Yan H, Zhuge Y, Zou X. Increased Glutamine Consumption in Cisplatin-Resistant Cells Has a Negative Impact on Cell Growth. Sci Rep 2018;8:4067. [PMID: 29511244 DOI: 10.1038/s41598-018-21831-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
44 Guo Y, Smith K, Petris MJ. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. J Biol Chem 2004;279:46393-9. [PMID: 15326162 DOI: 10.1074/jbc.M407777200] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
45 Arivarasu N, Fatima S, Mahmood R. Effect of cisplatin on brush border membrane enzymes and anti-oxidant system of rat intestine. Life Sciences 2007;81:393-8. [DOI: 10.1016/j.lfs.2007.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
46 Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, Pecora A, Suh KS. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res 2014;7:109. [PMID: 25477184 DOI: 10.1186/s13048-014-0109-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
47 Pathak HB, Zhou Y, Sethi G, Hirst J, Schilder RJ, Golemis EA, Godwin AK. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. PLoS One 2015;10:e0144126. [PMID: 26637171 DOI: 10.1371/journal.pone.0144126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
48 Huang C, Anderson M, Meister A. Amino acid sequence and function of the light subunit of rat kidney gamma-glutamylcysteine synthetase. Journal of Biological Chemistry 1993;268:20578-83. [DOI: 10.1016/s0021-9258(20)80764-9] [Cited by in Crossref: 121] [Article Influence: 4.3] [Reference Citation Analysis]
49 Jin L, Huo Y, Zheng Z, Jiang X, Deng H, Chen Y, Lian Q, Ge R, Deng H. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics 2014;13:3138-51. [PMID: 25096996 DOI: 10.1074/mcp.M113.033217] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
50 Jia Y, Zhang W, Liu H, Peng L, Yang Z, Lou J. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol 2012;69:377-85. [PMID: 21833590 DOI: 10.1007/s00280-011-1708-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lindenmeyer MT, Hrenn A, Kern C, Castro V, Murillo R, Müller S, Laufer S, Schulte-Mönting J, Siedle B, Merfort I. Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells. Bioorg Med Chem 2006;14:2487-97. [PMID: 16326104 DOI: 10.1016/j.bmc.2005.11.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
52 Neu M, Germershaus O, Mao S, Voigt K, Behe M, Kissel T. Crosslinked nanocarriers based upon poly(ethylene imine) for systemic plasmid delivery: In vitro characterization and in vivo studies in mice. Journal of Controlled Release 2007;118:370-80. [DOI: 10.1016/j.jconrel.2007.01.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
53 Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol 2012;83:1005-12. [PMID: 22138445 DOI: 10.1016/j.bcp.2011.11.016] [Cited by in Crossref: 101] [Cited by in F6Publishing: 103] [Article Influence: 10.1] [Reference Citation Analysis]
54 Pluchino LA, Choudhary S, Wang HC. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228. Cancer Lett 2016;381:124-32. [PMID: 27477899 DOI: 10.1016/j.canlet.2016.07.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
55 Knopf KM, Murphy BL, MacMillan SN, Baskin JM, Barr MP, Boros E, Wilson JJ. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. J Am Chem Soc 2017;139:14302-14. [PMID: 28948792 DOI: 10.1021/jacs.7b08640] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 22.0] [Reference Citation Analysis]
56 Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 2008;271:260-271. [PMID: 18657898 DOI: 10.1016/j.canlet.2008.06.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
57 Huang H, Lampson M, Efimov A, Yen TJ. Chromosome instability in tumor cells due to defects in Aurora B mediated error correction at kinetochores. Cell Cycle 2018;17:2622-36. [PMID: 30513041 DOI: 10.1080/15384101.2018.1553340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
58 Perez M, Lucena-Cacace A, Marín-Gómez LM, Padillo-Ruiz J, Robles-Frias MJ, Saez C, Garcia-Carbonero R, Carnero A. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget 2016;7:33111-24. [PMID: 27105527 DOI: 10.18632/oncotarget.8880] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
59 Pereira D, Assis J, Gomes M, Nogueira A, Medeiros R. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. Eur J Clin Pharmacol 2016;72:545-53. [PMID: 26803611 DOI: 10.1007/s00228-016-2015-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
60 Kimura A, Ohashi K, Naganuma A. Cisplatin upregulatesSaccharomyces cerevisiae genes involved in iron homeostasis through activation of the iron insufficiency-responsive transcription factor Aft1. J Cell Physiol 2007;210:378-84. [DOI: 10.1002/jcp.20845] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
61 Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009;69:3842-9. [PMID: 19383922 DOI: 10.1158/0008-5472.CAN-08-2246] [Cited by in Crossref: 109] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
62 Isonishi S, Hom DK, Eastman A, Howell SB. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line. Br J Cancer 1994;69:217-21. [PMID: 8297717 DOI: 10.1038/bjc.1994.42] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
63 Urata Y, Yamamoto H, Goto S, Tsushima H, Akazawa S, Yamashita S, Nagataki S, Kondo T. Long exposure to high glucose concentration impairs the responsive expression of gamma-glutamylcysteine synthetase by interleukin-1beta and tumor necrosis factor-alpha in mouse endothelial cells. J Biol Chem 1996;271:15146-52. [PMID: 8662965 DOI: 10.1074/jbc.271.25.15146] [Cited by in F6Publishing: 101] [Reference Citation Analysis]
64 Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, O'Dwyer PJ. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 2002;63:1699-707. [PMID: 12007573 DOI: 10.1016/s0006-2952(02)00841-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
65 Pratesi G, Bo L, Paolicchi A, Tonarelli P, Tongiani R, Zunino F. The role of the glutathione-dependent system in tumor sensitivity to cisplatin: A study of human tumor xenografts. Annals of Oncology 1995;6:283-9. [DOI: 10.1093/oxfordjournals.annonc.a059159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
66 Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30:42-59. [PMID: 18601945 DOI: 10.1016/j.mam.2008.05.005] [Cited by in Crossref: 1040] [Cited by in F6Publishing: 987] [Article Influence: 80.0] [Reference Citation Analysis]
67 Lee M, Jo A, Lee S, Kim JB, Chang Y, Nam JY, Cho H, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. 3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLoS One 2017;12:e0174271. [PMID: 28362858 DOI: 10.1371/journal.pone.0174271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
68 Lu SC. Regulation of glutathione synthesis. Current Topics in Cellular Regulation Volume 36. Elsevier; 2001. pp. 95-116. [DOI: 10.1016/s0070-2137(01)80004-2] [Cited by in Crossref: 133] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
69 Konkankit CC, Vaughn BA, MacMillan SN, Boros E, Wilson JJ. Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent. Inorg Chem 2019;58:3895-909. [PMID: 30793900 DOI: 10.1021/acs.inorgchem.8b03552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 12.5] [Reference Citation Analysis]
70 Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. Cancers (Basel) 2020;12:E3594. [PMID: 33271772 DOI: 10.3390/cancers12123594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
71 Corbin JM, Ruiz-Echevarría MJ. One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling. Int J Mol Sci 2016;17:E1208. [PMID: 27472325 DOI: 10.3390/ijms17081208] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
72 Kijima H, Tsuchida T, Kondo H, Iida T, Oshika Y, Nakamura M, Scanlon KJ, Kondo T, Tamaoki N. Hammerhead Ribozymes against γ-Glutamylcysteine Synthetase mRNA Down-Regulate Intracellular Glutathione Concentration of Mouse Islet Cells. Biochemical and Biophysical Research Communications 1998;247:697-703. [DOI: 10.1006/bbrc.1998.8878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
73 Branch P, Masson M, Aquilina G, Bignami M, Karran P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000;19:3138-45. [DOI: 10.1038/sj.onc.1203668] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 3.7] [Reference Citation Analysis]
74 Sugiyama A, Ohta T, Obata M, Takahashi K, Seino M, Nagase S. xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma. Oncol Lett 2020;20:2689-700. [PMID: 32782585 DOI: 10.3892/ol.2020.11813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
75 Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012;5:164. [PMID: 22452920 DOI: 10.1186/1756-0500-5-164] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
76 Thomas DJ, Birch PJ, Vickers J, Robinson M, Clifford S, Hall A, Neal DE. Glutathione-S-Transferase π Expression in Transitional Cell Carcinoma of the Bladder. British Journal of Urology 1993;72:740-3. [DOI: 10.1111/j.1464-410x.1993.tb16259.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Juvekar AS, Adwankar MK, Tongaonkar HB. Effect of Cisplatin-Based Chemotherapy on Emergence of Cisplatin Resistance, and its Correlation with Intracellular Glutathione Levels and Accumulation of p53 Protein in Human Ovarian Cancer. Cancer Biotherapy and Radiopharmaceuticals 2000;15:295-300. [DOI: 10.1089/108497800414392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
78 Li S, Liu Y, Li J, Zhao X, Yu D. Mechanisms of Ferroptosis and Application to Head and Neck Squamous Cell Carcinoma Treatments. DNA Cell Biol 2021;40:720-32. [PMID: 33979530 DOI: 10.1089/dna.2021.0023] [Reference Citation Analysis]
79 Chang Q, Ornatsky OI, Siddiqui I, Straus R, Baranov VI, Hedley DW. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. Sci Rep 2016;6:36641. [PMID: 27812005 DOI: 10.1038/srep36641] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
80 Cai J, Huang ZZ, Lu SC. Differential regulation of gamma-glutamylcysteine synthetase heavy and light subunit gene expression. Biochem J 1997;326 ( Pt 1):167-72. [PMID: 9337864 DOI: 10.1042/bj3260167] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 3.4] [Reference Citation Analysis]
81 Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C, Wei Y. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 2012;287:68-80. [PMID: 22052903 DOI: 10.1074/jbc.M111.271205] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
82 Doucette KA, Hassell KN, Crans DC. Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs. J Inorg Biochem 2016;165:56-70. [PMID: 27751591 DOI: 10.1016/j.jinorgbio.2016.09.013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 10.4] [Reference Citation Analysis]
83 Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, Mitsumoto M, Kohno K, Kuwano M, Nakano H. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999;85:2450-4. [DOI: 10.1002/(sici)1097-0142(19990601)85:11<2450::aid-cncr21>3.0.co;2-u] [Cited by in Crossref: 73] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
84 Flaherty KT, Stevenson JP, Redlinger M, Algazy KM, Giantonio B, O’dwyer PJ. A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemother Pharmacol 2004;53:404-8. [DOI: 10.1007/s00280-003-0754-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
85 Moghaddas S, Majmudar P, Marin R, Dezvareh H, Qi C, Soans E, Bose RN. Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets. Inorganica Chimica Acta 2012;393:173-81. [DOI: 10.1016/j.ica.2012.05.040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
86 Woods JS, Kavanagh TJ, Corral J, Reese AW, Diaz D, Ellis ME. The Role of Glutathione in Chronic Adaptation to Oxidative Stress: Studies in a Normal Rat Kidney Epithelial (NRK52E) Cell Model of Sustained Upregulation of Glutathione Biosynthesis. Toxicology and Applied Pharmacology 1999;160:207-16. [DOI: 10.1006/taap.1999.8774] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
87 Oguri T, Fujiwara Y, Katoh O, Daga H, Ishikawa N, Fujitaka K, Yamasaki M, Yokozaki M, Isobe T, Ishioka S, Yamakido M. Glutathione S-transferase-π gene expression and platinum drug exposure in human lung cancer. Cancer Letters 2000;156:93-9. [DOI: 10.1016/s0304-3835(00)00447-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
88 Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. Cancer Res 2020;80:4514-26. [PMID: 32859605 DOI: 10.1158/0008-5472.CAN-19-3971] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
89 Hamilton D, Loignon M, Alaoui-Jamali MA, Batist G. Novel use of the fluorescent dye 5-(and-6)-chloromethyl SNARF-1 acetate for the measurement of intracellular glutathione in leukemic cells and primary lymphocytes. Cytometry A 2007;71:709-15. [PMID: 17623874 DOI: 10.1002/cyto.a.20433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
90 Tagliabue G, Ubezio P, Balconi G, Mascellani E, D'incalci M, Pifferi A, Geroni C. Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to dna-interacting anti-neoplastic agents. Int J Cancer 1993;54:435-42. [DOI: 10.1002/ijc.2910540314] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
91 Fletcher NM, Belotte J, Saed MG, Memaj I, Diamond MP, Morris RT, Saed GM. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer. Free Radic Biol Med 2017;102:122-32. [PMID: 27890641 DOI: 10.1016/j.freeradbiomed.2016.11.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
92 Shantabi L, Jagetia GC, Moirangthem DS, Nongalleima K. Anticancer activity of an ehnomedicinal plant Croton caudatus Geiseler, Kam sabut in cultured HeLa cells. Biocatalysis and Agricultural Biotechnology 2020;23:101500. [DOI: 10.1016/j.bcab.2020.101500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Scoles DR, Pavelka J, Cass I, Tran H, Baldwin RL, Armstrong K, Karlan BY. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecologic Oncology 2007;104:120-8. [DOI: 10.1016/j.ygyno.2006.07.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
94 Chang LS. The functional involvement of Lys-38 in the heavy subunit of rat kidney gamma-glutamylcysteine synthetase: chemical modification and mutagenesis studies. J Protein Chem 1996;15:321-6. [PMID: 8804580 DOI: 10.1007/BF01887121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
95 Choudhary S, Sood S, Wang HC. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228. Biochem Biophys Res Commun 2013;436:325-30. [PMID: 23743194 DOI: 10.1016/j.bbrc.2013.05.102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
96 Burg D, Mulder GJ. Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab Rev. 2002;34:821-863. [PMID: 12487151 DOI: 10.1081/DMR-120015695] [Cited by in Crossref: 54] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
97 Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li K, Fang Y, Weng D, Weng Y, Liao S, Han Z, Liu R, Zhu T, Wang S, Xu G, Meng L, Zhou J, Ma D. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer 2011;11:399. [PMID: 21933447 DOI: 10.1186/1471-2407-11-399] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
98 Bessede G, Miguet C, Gambert P, Neel D, Lizard G. Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to γ‐glutamyl transpeptidase activity. FASEB j 2001;15:1927-40. [DOI: 10.1096/fj.00-0848com] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
99 Barhoumi R, Bowen JA, Stein LS, Echols J, Burghardt RC. Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. Cytometry 1993;14:747-56. [DOI: 10.1002/cyto.990140707] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 1.7] [Reference Citation Analysis]
100 Bugarčić ŽD, Bogojeski J, Petrović B, Hochreuther S, van Eldik R. Mechanistic studies on the reactions of platinum(ii) complexes with nitrogen- and sulfur-donor biomolecules. Dalton Trans 2012;41:12329. [DOI: 10.1039/c2dt31045g] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
101 Fujima N, Yoshida D, Sakashita T, Homma A, Tsukahara A, Tha KK, Kudo K, Shirato H. Usefulness of Pseudocontinuous Arterial Spin-Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period. AJNR Am J Neuroradiol 2016;37:342-8. [PMID: 26427828 DOI: 10.3174/ajnr.A4513] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
102 Gao F, Yang X, Luo X, Xue X, Qian C, Sun M. Photoactivated Nanosheets Accelerate Nucleus Access of Cisplatin for Drug‐Resistant Cancer Therapy. Adv Funct Mater 2020;30:2001546. [DOI: 10.1002/adfm.202001546] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
103 Biterova EI, Barycki JJ. Structural basis for feedback and pharmacological inhibition of Saccharomyces cerevisiae glutamate cysteine ligase. J Biol Chem 2010;285:14459-66. [PMID: 20220146 DOI: 10.1074/jbc.M110.104802] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
104 Takai M, Nakagawa T, Tanabe A, Terai Y, Ohmichi M, Asahi M. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma. Cancer Biol Ther 2015;16:325-35. [PMID: 25756515 DOI: 10.1080/15384047.2014.1002362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
105 Abe T, Gotoh S, Higashi K. Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells. Biochemical Pharmacology 1999;58:69-76. [DOI: 10.1016/s0006-2952(99)00049-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
106 Coriat R, Marut W, Leconte M, Ba LB, Vienne A, Chéreau C, Alexandre J, Weill B, Doering M, Jacob C, Nicco C, Batteux F. The organotelluride catalyst LAB027 prevents colon cancer growth in the mice. Cell Death Dis 2011;2:e191. [PMID: 21833029 DOI: 10.1038/cddis.2011.73] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
107 Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I Study of Continuous-Infusion L-S,R-Buthionine Sulfoximine With Intravenous Melphalan. JNCI Journal of the National Cancer Institute 1997;89:1789-96. [DOI: 10.1093/jnci/89.23.1789] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 4.9] [Reference Citation Analysis]
108 Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation. Tumour Biol 2016;37:14259-69. [PMID: 27581819 DOI: 10.1007/s13277-016-5290-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
109 Nakajima M, Watanabe B, Han L, Shimizu B, Wada K, Fukuyama K, Suzuki H, Hiratake J. Glutathione-analogous peptidyl phosphorus esters as mechanism-based inhibitors of γ-glutamyl transpeptidase for probing cysteinyl-glycine binding site. Bioorg Med Chem 2014;22:1176-94. [PMID: 24411479 DOI: 10.1016/j.bmc.2013.12.034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
110 Wahba J, Natoli M, Whilding LM, Parente-Pereira AC, Jung Y, Zona S, Lam EW, Smith JR, Maher J, Ghaem-Maghami S. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Cancer Immunol Immunother 2018;67:1753-65. [PMID: 30167862 DOI: 10.1007/s00262-018-2199-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
111 Ben Mahmoud L, Mdhaffar M, Ghozzi H, Ammar M, Hakim A, Atheymen R, Sahnoun Z, Elloumi M, Zeghal K. Oxidative Stress in Tunisian Patients With Acute Lymphoblastic Leukemia and Its Involvement in Leukemic Relapse. J Pediatr Hematol Oncol 2017;39:e124-30. [PMID: 28306688 DOI: 10.1097/MPH.0000000000000793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
112 Roth E. The cell- and immune-modulating properties of glutamine. Diet, Immunity and Inflammation. Elsevier; 2013. pp. 502-22. [DOI: 10.1533/9780857095749.3.502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
113 Schulte RR, Linkous AG, Hallahan DE, Yazlovitskaya EM. Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Cancer Lett 2011;304:137-43. [PMID: 21397389 DOI: 10.1016/j.canlet.2011.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
114 Franklin CC, Krejsa CM, Pierce RH, White CC, Fausto N, Kavanagh TJ. Caspase-3-Dependent Cleavage of the Glutamate-L-Cysteine Ligase Catalytic Subunit during Apoptotic Cell Death. Am J Pathol 2002;160:1887-94. [PMID: 12000740 DOI: 10.1016/S0002-9440(10)61135-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
115 Franzini M, Corti A, Lorenzini E, Paolicchi A, Pompella A, De Cesare M, Perego P, Gatti L, Leone R, Apostoli P, Zunino F. Modulation of cell growth and cisplatin sensitivity by membrane γ-glutamyltransferase in melanoma cells. European Journal of Cancer 2006;42:2623-30. [DOI: 10.1016/j.ejca.2006.04.016] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
116 Luo T, Yu J, Nguyen J, Wang CR, Bristow RG, Jaffray DA, Zhou XZ, Lu KP, Lu QB. Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci U S A 2012;109:10175-80. [PMID: 22685209 DOI: 10.1073/pnas.1203451109] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
117 Kamiyama A, Nakajima M, Han L, Wada K, Mizutani M, Tabuchi Y, Kojima-Yuasa A, Matsui-Yuasa I, Suzuki H, Fukuyama K, Watanabe B, Hiratake J. Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity. Bioorg Med Chem 2016;24:5340-52. [PMID: 27622749 DOI: 10.1016/j.bmc.2016.08.050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
118 Ho SB, Yan P, Dahiya R, Neuschwander-tetri BA, Basbaum C, Kim YS. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance. J Cell Physiol 1994;160:213-26. [DOI: 10.1002/jcp.1041600202] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.1] [Reference Citation Analysis]
119 Chen P, Wang L, Sun S, Zhou Q, Zeng Z, Hu M, Hussain M, Lu C, Du H. High-throughput screening suggests glutathione synthetase as an anti-tumor target of polydatin using human proteome chip. Int J Biol Macromol 2020;161:1230-9. [PMID: 32544581 DOI: 10.1016/j.ijbiomac.2020.06.061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002;93:723-8. [PMID: 12079522 DOI: 10.1111/j.1349-7006.2002.tb01312.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
121 Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T, Isaka K. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. Tumour Biol 2011;32:399-408. [PMID: 21113744 DOI: 10.1007/s13277-010-0133-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
122 Bajic VP, Van Neste C, Obradovic M, Zafirovic S, Radak D, Bajic VB, Essack M, Isenovic ER. Glutathione "Redox Homeostasis" and Its Relation to Cardiovascular Disease. Oxid Med Cell Longev 2019;2019:5028181. [PMID: 31210841 DOI: 10.1155/2019/5028181] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
123 Godbout JP, Pesavento J, Hartman ME, Manson SR, Freund GG. Methylglyoxal Enhances Cisplatin-induced Cytotoxicity by Activating Protein Kinase Cδ. Journal of Biological Chemistry 2002;277:2554-61. [DOI: 10.1074/jbc.m100385200] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
124 Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG. Metallothionein in testicular germ cell tumors and drug resistance. Clinical correlation. Cancer 1993;72:3029-35. [PMID: 8221570 DOI: 10.1002/1097-0142(19931115)72:10<3029::aid-cncr2820721027>3.0.co;2-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
125 Lu SC, Huang ZZ, Yang H, Tsukamoto H. Effect of thioacetamide on the hepatic expression of gamma-glutamylcysteine synthetase subunits in the Rat. Toxicol Appl Pharmacol. 1999;159:161-168. [PMID: 10486302 DOI: 10.1006/taap.1999.8729] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.7] [Reference Citation Analysis]
126 Ishikawa T, Wright C, Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. Journal of Biological Chemistry 1994;269:29085-93. [DOI: 10.1016/s0021-9258(19)62016-8] [Cited by in Crossref: 106] [Article Influence: 3.9] [Reference Citation Analysis]
127 Ohashi K, Kajiya K, Inaba S, Hasegawa T, Seko Y, Furuchi T, Naganuma A. Copper(II) protects yeast against the toxicity of cisplatin independently of the induction of metallothionein and the inhibition of platinum uptake. Biochem Biophys Res Commun 2003;310:148-52. [PMID: 14511662 DOI: 10.1016/j.bbrc.2003.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
128 Onodera T, Momose I, Adachi H, Yamazaki Y, Sawa R, Ohba SI, Kawada M. Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition. J Biol Chem 2020;295:16678-90. [PMID: 32978257 DOI: 10.1074/jbc.RA120.013893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 Urata Y, Yamaguchi M, Higashiyama Y, Ihara Y, Goto S, Kuwano M, Horiuchi S, Sumikawa K, Kondo T. Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radical Biology and Medicine 2002;32:688-701. [DOI: 10.1016/s0891-5849(01)00823-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
130 Han Y, Yin W, Li J, Zhao H, Zha Z, Ke W, Wang Y, He C, Ge Z. Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers. J Control Release 2018;273:30-9. [PMID: 29371047 DOI: 10.1016/j.jconrel.2018.01.019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 16.3] [Reference Citation Analysis]
131 Ishibashi M, Toyoshima M, Zhang X, Hasegawa-Minato J, Shigeta S, Usui T, Kemp CJ, Grandori C, Kitatani K, Yaegashi N. Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer. Sci Rep 2018;8:13207. [PMID: 30181600 DOI: 10.1038/s41598-018-31069-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
132 Nakamura TY, Yamamoto I, Kanno Y, Shiba Y, Goshima K. Metabolic coupling of glutathione between mouse and quail cardiac myocytes and its protective role against oxidative stress. Circ Res 1994;74:806-16. [DOI: 10.1161/01.res.74.5.806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
133 Chen D, Wang R, Meng X, Yan H, Jiang S, Feng R, Zhu K, Xu X, Dou X, Jin L. Prognostic value of serum γ-glutamyl transferase in unresectable hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization combined with conformal radiotherapy. Oncol Lett 2014;8:2298-304. [PMID: 25289109 DOI: 10.3892/ol.2014.2456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
134 Shaughnessy F, Mariotti E, Shaw KP, Eykyn TR, Blower PJ, Siow R, Southworth R. Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM). EJNMMI Res 2014;4:40. [PMID: 26055939 DOI: 10.1186/s13550-014-0040-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
135 Suryadi J, Bierbach U. DNA Metalating-Intercalating Hybrid Agents for the Treatment of Chemoresistant Cancers. Chem Eur J 2012;18:12926-34. [DOI: 10.1002/chem.201202050] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
136 Siddik ZH. Cisplatin Resistance. In: Teicher BA, editor. Cancer Drug Resistance. Totowa: Humana Press; 2006. pp. 283-307. [DOI: 10.1007/978-1-59745-035-5_16] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
137 Bradbury A, O'Donnell R, Drew Y, Curtin NJ, Sharma Saha S. Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers (Basel) 2020;12:E1939. [PMID: 32709004 DOI: 10.3390/cancers12071939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 Day JM, Foster PA, Tutill HJ, Newman SP, Ho YT, Leese MP, Potter BV, Reed MJ, Purohit A. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer 2009;100:476-86. [PMID: 19156141 DOI: 10.1038/sj.bjc.6604873] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
139 Schröder CP, Godwin AK, O'dwyer PJ, Tew KD, Hamilton TC, Ozols RF. Glutathione and Drug Resistance. Cancer Investigation 2009;14:158-68. [DOI: 10.3109/07357909609018891] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
140 Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279. [PMID: 14576837 DOI: 10.1038/sj.onc.1206933] [Cited by in Crossref: 2083] [Cited by in F6Publishing: 1948] [Article Influence: 115.7] [Reference Citation Analysis]
141 Perquin M, Oster T, Maul A, Froment N, Untereiner M, Bagrel D. The glutathione-related detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues. Cancer Lett 2000;158:7-16. [PMID: 10940503 DOI: 10.1016/s0304-3835(00)00481-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
142 Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975-84. [PMID: 18829555 DOI: 10.1158/0008-5472.CAN-08-1401] [Cited by in Crossref: 254] [Cited by in F6Publishing: 136] [Article Influence: 19.5] [Reference Citation Analysis]
143 Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cunningham MJ, Dubowy RL, Souid A. Kinetics of Cisplatin Binding to Cellular DNA and Modulations by Thiol-Blocking Agents and Thiol Drugs. Drug Metab Dispos 2002;30:183-90. [DOI: 10.1124/dmd.30.2.183] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 3.7] [Reference Citation Analysis]
144 Rahman I, MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol 1999;277:L1067-88. [PMID: 10600876 DOI: 10.1152/ajplung.1999.277.6.L1067] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 4.2] [Reference Citation Analysis]
145 Xu JM, Azzariti A, Severino M, Lu B, Colucci G, Paradiso A. Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol 2003;66:551-63. [PMID: 12906920 DOI: 10.1016/s0006-2952(03)00291-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
146 Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes—state of the art and future perspectives. Reviews of Physiology, Biochemistry and Pharmacology. Berlin: Springer Berlin Heidelberg; 2003. pp. 1-53. [DOI: 10.1007/s10254-002-0001-x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 264] [Reference Citation Analysis]
147 Chikhi N, Holic N, Guellaen G, Laperche Y. Gamma-glutamyl transpeptidase gene organization and expression: a comparative analysis in rat, mouse, pig and human species. Comp Biochem Physiol B Biochem Mol Biol 1999;122:367-80. [PMID: 10392451 DOI: 10.1016/s0305-0491(99)00013-9] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
148 Song N, Kim D, Kim E, Na H, Kim N, Suh Y, Surh Y. Multidrug Resistance-Associated Protein 1 Mediates 15-Deoxy-Δ 12,14 -prostaglandin J 2 -Induced Expression of Glutamate Cysteine Ligase Expression via Nrf2 Signaling in Human Breast Cancer Cells. Chem Res Toxicol 2011;24:1231-41. [DOI: 10.1021/tx200090n] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
149 Oguri T, Fujiwara Y, Miyazaki M, Takahashi T, Kurata T, Yokozaki M, Ohashi N, Isobe T, Katoh O, Yamakido M. Induction of λ-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients. Annals of Oncology 1999;10:455-60. [DOI: 10.1023/a:1008317502977] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Zhang R, Niu Y, Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett 2010;192:108-14. [PMID: 19853026 DOI: 10.1016/j.toxlet.2009.10.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
151 Liu H, Song W, Zhang S, Chan KS, Guo Z, Shen Z. A ratiometric fluorescent probe for real-time monitoring of intracellular glutathione fluctuations in response to cisplatin. Chem Sci 2020;11:8495-501. [PMID: 34123110 DOI: 10.1039/d0sc02889d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
152 Oguri T, Katoh O, Takahashi T, Isobe T, Kuramoto K, Hirata S, Yamakido M, Watanabe H. The Krüppel-type zinc finger family gene, HKR1, is induced in lung cancer by exposure to platinum drugs. Gene 1998;222:61-7. [PMID: 9813242 DOI: 10.1016/s0378-1119(98)00464-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
153 Bartolami S, Planche M, Pujol R. Sulphhydryl-modifying Reagents Alter Ototoxin Block of Muscarinic Receptor-linked Phosphoinositide Turnover in the Cochlea. European Journal of Neuroscience 1993;5:832-8. [DOI: 10.1111/j.1460-9568.1993.tb00935.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
154 Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X, Wu C. Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials 2021;277:121110. [PMID: 34482088 DOI: 10.1016/j.biomaterials.2021.121110] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158:610-620. [PMID: 19732064 DOI: 10.1111/j.1476-5381.2009.00341.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
156 Wang X, Wang H, Li X. Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumor Biol 2013;34:2275-81. [DOI: 10.1007/s13277-013-0769-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
157 Layek B, Shetty M, Nethi SK, Sehgal D, Starr TK, Prabha S. Mesenchymal Stem Cells As Guideposts for Nanoparticle-Mediated Targeted Drug Delivery in Ovarian Cancer. Cancers (Basel) 2020;12:E965. [PMID: 32295145 DOI: 10.3390/cancers12040965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
158 Harper AK, Fletcher NM, Fan R, Morris RT, Saed GM. Heat Shock Protein 60 (HSP60) Serves as a Potential Target for the Sensitization of Chemoresistant Ovarian Cancer Cells. Reprod Sci 2020;27:1030-6. [DOI: 10.1007/s43032-019-00089-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
159 Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu ZQ, Chen XP, Zhang W, Zhou HH. Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Sci Rep 2017;7:18. [PMID: 28154416 DOI: 10.1038/s41598-017-00050-w] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
160 Casas A, Di Venosa G, Hasan T, Al Batlle. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011;18:2486-515. [PMID: 21568910 DOI: 10.2174/092986711795843272] [Cited by in Crossref: 174] [Cited by in F6Publishing: 156] [Article Influence: 17.4] [Reference Citation Analysis]
161 Miller AC, Samid D. Tumor resistance to oxidative stress: Association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 1995;60:249-54. [DOI: 10.1002/ijc.2910600220] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
162 Marker SC, MacMillan SN, Zipfel WR, Li Z, Ford PC, Wilson JJ. Photoactivated in Vitro Anticancer Activity of Rhenium(I) Tricarbonyl Complexes Bearing Water-Soluble Phosphines. Inorg Chem 2018;57:1311-31. [PMID: 29323880 DOI: 10.1021/acs.inorgchem.7b02747] [Cited by in Crossref: 76] [Cited by in F6Publishing: 51] [Article Influence: 25.3] [Reference Citation Analysis]
163 Gokduman K. Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study. Nanomedicine (Lond) 2019;14:3177-91. [PMID: 31724481 DOI: 10.2217/nnm-2019-0126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
164 Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther 2020;5:108. [PMID: 32606298 DOI: 10.1038/s41392-020-00216-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 21.0] [Reference Citation Analysis]
165 Tagashira M, Nozato N, Isonishi S, Okamoto A, Ochiai K, Ohtake Y. 5-Hydroxy-4-oxo- L -norvaline Depletes Intracellular Glutathione: a New Modulator of Drug Resistance. Bioscience, Biotechnology, and Biochemistry 2014;63:1953-8. [DOI: 10.1271/bbb.63.1953] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
166 Penketh PG, Shyam K, Sartorelli AC. Mechanisms of Resistance to Alkylating Agents. In: Hait WN, editor. Drug Resistance. Boston: Springer US; 1996. pp. 65-81. [DOI: 10.1007/978-1-4613-1267-3_3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
167 Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer 2011;129:1425-34. [PMID: 21128223 DOI: 10.1002/ijc.25814] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
168 Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA. 1994;91:13033-13037. [PMID: 7809167 DOI: 10.1073/pnas.91.26.13033] [Cited by in Crossref: 379] [Cited by in F6Publishing: 395] [Article Influence: 14.6] [Reference Citation Analysis]
169 Stephens LJ, Levina A, Trinh I, Blair VL, Werrett MV, Lay PA, Andrews PC. Ruthenium(II)-Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells. Chembiochem 2020;21:1188-200. [PMID: 31701616 DOI: 10.1002/cbic.201900676] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Mulcahy RT, Bailey HH, Gipp JJ. Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 1994;34:67-71. [PMID: 7513621 DOI: 10.1007/BF00686114] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
171 Daubeuf S, Accaoui MJ, Pettersen I, Huseby NE, Visvikis A, Galteau MM. Differential regulation of gamma-glutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta 2001;1568:67-73. [PMID: 11731087 DOI: 10.1016/s0304-4165(01)00201-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
172 Nešić M, Popović I, Leskovac A, Petković M. Biological activity and binding properties of [Ru(II)(dcbpy)2Cl2] complex to bovine serum albumin, phospholipase A2 and glutathione. Biometals 2016;29:921-33. [PMID: 27515969 DOI: 10.1007/s10534-016-9964-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
173 Sasada T, Nakamura H, Ueda S, Iwata S, Ueno M, Takabayashi A, Yodoi J. Secretion of thioredoxin enhances cellular resistance to cis-diamminedichloroplatinum (II). Antioxid Redox Signal 2000;2:695-705. [PMID: 11213475 DOI: 10.1089/ars.2000.2.4-695] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
174 Huo D, Jiang X, Hu Y. Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. Adv Mater 2020;32:e1904337. [PMID: 31663198 DOI: 10.1002/adma.201904337] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 19.5] [Reference Citation Analysis]
175 Zheng J, Wu Y, Xing D, Zhang T. Synchronous detection of glutathione/hydrogen peroxide for monitoring redox status in vivo with a ratiometric upconverting nanoprobe. Nano Res 2019;12:931-8. [DOI: 10.1007/s12274-019-2327-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
176 Zhu Z, Mukhina S, Zhu T, Mertani HC, Lee K, Lobie PE. p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 2005;24:3774-85. [DOI: 10.1038/sj.onc.1208541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
177 Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer 2009;9:368. [PMID: 19835627 DOI: 10.1186/1471-2407-9-368] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
178 Holford J, Beale P, Boxall F, Sharp S, Kelland L. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. European Journal of Cancer 2000;36:1984-90. [DOI: 10.1016/s0959-8049(00)00192-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
179 Possato B, Dalmolin LF, Pereira LM, Alves JQ, Silva RTC, Gelamo RV, Yatsuda AP, Lopez RFV, de Albuquerque S, Leite NB, Maia PIDS. Gold(III) complexes with thiosemicarbazonate ligands as potential anticancer agents: Cytotoxicity and interactions with biomolecular targets. Eur J Pharm Sci 2021;162:105834. [PMID: 33826936 DOI: 10.1016/j.ejps.2021.105834] [Reference Citation Analysis]
180 Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1-10. [PMID: 12506132 DOI: 10.1097/01.asn.0000042803.28024.92] [Cited by in Crossref: 199] [Cited by in F6Publishing: 73] [Article Influence: 11.1] [Reference Citation Analysis]
181 Amable L, Fain J, Gavin E, Reed E. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug. Oncol Rep 2014;32:469-74. [PMID: 24926795 DOI: 10.3892/or.2014.3257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
182 Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary: . Obstetrics & Gynecology 2002;100:281-7. [DOI: 10.1097/00006250-200208000-00014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
183 Yamada T, Endo R, Gotoh M, Hirohashi S. Identification of semaphorin E as a non-MDR drug resistance gene of human cancers. Proc Natl Acad Sci USA. 1997;94:14713-14718. [PMID: 9405678 DOI: 10.1073/pnas.94.26.14713] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 3.0] [Reference Citation Analysis]
184 Ohta N, Inagaki K, Muta H, Yotsuyanagi T, Matsuo T. Reaction of oxidized glutathione with cis- and trans-diamminedichloroplatinum(II) and their aquated complexes through the disulfide bond. International Journal of Pharmaceutics 1998;161:15-21. [DOI: 10.1016/s0378-5173(97)00323-2] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
185 Bian C, Wu R, Cho K, Yu X. Loss of BRCA1-A complex function in RAP80 null tumor cells. PLoS One 2012;7:e40406. [PMID: 22792303 DOI: 10.1371/journal.pone.0040406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
186 Hermann G, Heffeter P, Falta T, Berger W, Hann S, Koellensperger G. In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics 2013;5:636. [DOI: 10.1039/c3mt20251h] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
187 Njalsson R, Norgren S, Larsson A, Huang CS, Anderson ME, Luo JL. Cooperative binding of gamma-glutamyl substrate to human glutathione synthetase. Biochem Biophys Res Commun 2001;289:80-4. [PMID: 11708780 DOI: 10.1006/bbrc.2001.5961] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
188 Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 2000;60:1611-9. [PMID: 11077043 DOI: 10.1016/s0006-2952(00)00448-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
189 Bologna G, Lanuti P, D'Ambrosio P, Tonucci L, Pierdomenico L, D'Emilio C, Celli N, Marchisio M, d'Alessandro N, Santavenere E, Bressan M, Miscia S. Water-soluble platinum phthalocyanines as potential antitumor agents. Biometals 2014;27:575-89. [PMID: 24699848 DOI: 10.1007/s10534-014-9730-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
190 Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS One 2016;11:e0165385. [PMID: 27788210 DOI: 10.1371/journal.pone.0165385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
191 Sîrbu A, Palamarciuc O, Babak MV, Lim JM, Ohui K, Enyedy EA, Shova S, Darvasiová D, Rapta P, Ang WH, Arion VB. Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells. Dalton Trans 2017;46:3833-47. [PMID: 28271099 DOI: 10.1039/c7dt00283a] [Cited by in Crossref: 47] [Cited by in F6Publishing: 9] [Article Influence: 15.7] [Reference Citation Analysis]
192 Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 1999;274:12061-6. [PMID: 10207030 DOI: 10.1074/jbc.274.17.12061] [Cited by in Crossref: 176] [Cited by in F6Publishing: 162] [Article Influence: 8.0] [Reference Citation Analysis]
193 Yao K, Gietema JA, Shida S, Selvakumaran M, Fonrose X, Haas NB, Testa J, O'Dwyer PJ. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br J Cancer. 2005;93:1356-1363. [PMID: 16333244 DOI: 10.1038/sj.bjc.6602864] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
194 Sankar RK, Kumbhare RS, Dharmaraja AT, Chakrapani H. A phenacrylate scaffold for tunable thiol activation and release. Chem Commun (Camb) 2014;50:15323-6. [PMID: 25347732 DOI: 10.1039/c4cc07343f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
195 Jänicke RU, Sohn D, Schulze-osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008;15:959-76. [DOI: 10.1038/cdd.2008.33] [Cited by in Crossref: 137] [Cited by in F6Publishing: 116] [Article Influence: 10.5] [Reference Citation Analysis]
196 Shimizu T, Iwanaga M, Yasunaga A, Urata Y, Goto S, Shibata S, Kondo T. Protective role of glutathione synthesis on radiation-induced DNA damage in rabbit brain. Cell Mol Neurobiol 1998;18:299-310. [PMID: 9590560 DOI: 10.1023/a:1022525214871] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
197 Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998;27:187-201. [PMID: 19002792 DOI: 10.1023/A:1008016922425] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
198 Manandhar S, Lee S, Kwak M. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells. Arch Pharm Res 2010;33:717-26. [DOI: 10.1007/s12272-010-0511-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
199 Nagata J, Kijima H, Hatanaka H, Asai S, Miyachi H, Takagi A, Miwa T, Mine T, Yamazaki H, Nakamura M. Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. Biochem Biophys Res Commun. 2001;286:406-413. [PMID: 11500053 DOI: 10.1006/bbrc.2001.5399] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
200 Levy EJ, Anderson ME, Meister A. Transport of glutathione diethyl ester into human cells. Proc Natl Acad Sci U S A 1993;90:9171-5. [PMID: 8415673 DOI: 10.1073/pnas.90.19.9171] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 2.8] [Reference Citation Analysis]
201 Ueno Y, Kizaki M, Nakagiri R, Kamiya T, Sumi H, Osawa T. Dietary glutathione protects rats from diabetic nephropathy and neuropathy. J Nutr 2002;132:897-900. [PMID: 11983810 DOI: 10.1093/jn/132.5.897] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 3.5] [Reference Citation Analysis]
202 Graber R, Losa GA. Apoptosis in human lymphoblastoid cells induced by acivicin, a specific γ glutamyltransferase inhibitor. Int J Cancer 1995;62:443-8. [DOI: 10.1002/ijc.2910620414] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
203 Hamilton TC, Johnson SW, Godwin AK. Molecular biology of gynecologic malignancies. In: Ozols RF, editor. Gynecologic Oncology. Boston: Springer US; 1998. pp. 103-14. [DOI: 10.1007/978-1-4615-5447-9_2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
204 Hamilton D, Fotouhi-ardakani N, Batist G. The Glutathione System in Alkylator Resistance. In: Andersson B, Murray D, editors. Clinically Relevant Resistance in Cancer Chemotherapy. Boston: Springer US; 2002. pp. 67-87. [DOI: 10.1007/978-1-4615-1173-1_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
205 Hamilton G. Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer. Expert Opin Drug Metab Toxicol 2013;9:1381-90. [PMID: 23829480 DOI: 10.1517/17425255.2013.815724] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
206 Palanichamy K, Sreejayan N, Ontko AC. Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes. J Inorg Biochem 2012;106:32-42. [PMID: 22112837 DOI: 10.1016/j.jinorgbio.2011.08.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
207 Wang S, Wu MJ, Higgins VJ, Aldrich-wright JR. Comparative analyses of cytotoxicity and molecular mechanisms between platinum metallointercalators and cisplatin. Metallomics 2012;4:950. [DOI: 10.1039/c2mt20102j] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
208 Han CY, Patten DA, Richardson RB, Harper ME, Tsang BK. Tumor metabolism regulating chemosensitivity in ovarian cancer. Genes Cancer 2018;9:155-75. [PMID: 30603053 DOI: 10.18632/genesandcancer.176] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
209 Chen S, Gao W, Zhang MJ, Chan JY, Wong TS. Curcumin enhances cisplatin sensitivity by suppressing NADPH oxidase 5 expression in human epithelial cancer. Oncol Lett 2019;18:2132-9. [PMID: 31423287 DOI: 10.3892/ol.2019.10479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
210 Pattarawat P, Hong T, Wallace S, Hu Y, Donnell R, Wang TH, Tsai CL, Wang J, Wang HR. Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma. Br J Cancer 2020;123:226-39. [PMID: 32390005 DOI: 10.1038/s41416-020-0877-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
211 Chowanadisai W, Messerli SM, Miller DH, Medina JE, Hamilton JW, Messerli MA, Brodsky AS. Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors. PLoS One 2016;11:e0151089. [PMID: 26986722 DOI: 10.1371/journal.pone.0151089] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
212 Blumberg D, Hochwald S, Pinto J, Burt M. Altered glutathione metabolism in the tumor-bearing state. Annals of Surgical Oncology 1995;2:332-5. [DOI: 10.1007/bf02307066] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
213 Yao J, Li T, Shi X, Wang Y, Fang S, Wang H. A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies. Acta Biomater 2021;130:409-22. [PMID: 34087447 DOI: 10.1016/j.actbio.2021.05.047] [Reference Citation Analysis]
214 Canitrot Y, Frit P, Salles B. Deficient Apoptotic Process in Cisplatin-Resistant L1210 Cells Cannot Account for the Cellular Response to Various Drug Treatments. Biochemical and Biophysical Research Communications 1997;234:573-7. [DOI: 10.1006/bbrc.1997.6674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
215 Tung CH, Kuo LW, Huang MF, Wu YY, Tsai YT, Wu JE, Hsu KF, Chen YL, Hong TM. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer. Oncogene 2020;39:862-76. [PMID: 31570789 DOI: 10.1038/s41388-019-1025-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
216 Lawrence D, Engelsberg B, Farid R, Hughes E, Billings P. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA. Journal of Biological Chemistry 1993;268:23940-5. [DOI: 10.1016/s0021-9258(20)80475-x] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
217 Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ Jr. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Mol Ther 2020;28:548-60. [PMID: 31870622 DOI: 10.1016/j.ymthe.2019.11.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
218 Chen P, Stone J, Sullivan G, Drisko JA, Chen Q. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med 2011;51:681-7. [PMID: 21672627 DOI: 10.1016/j.freeradbiomed.2011.05.031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
219 Oguri T, Fujiwara Y, Isobe T, Katoh O, Watanabe H, Yamakido M. Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 1998;77:1089-96. [PMID: 9569044 DOI: 10.1038/bjc.1998.181] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
220 Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of Cisplatin Cytotoxicity and Cisplatin-Induced DNA Cross-Links in HepG2 Cells by Regulation of Glutathione-Related Mechanisms. Mol Pharmacol 2001;59:837-43. [DOI: 10.1124/mol.59.4.837] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 3.3] [Reference Citation Analysis]
221 Kolfschoten GM, Pinedo HM, Scheffer PG, Schlüper HM, Erkelens CA, Boven E. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol 2000;76:362-8. [PMID: 10684711 DOI: 10.1006/gyno.1999.5689] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
222 Kurokawa H, Nishio K, Ishida T, Arioka H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijo N. Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the gamma-glutamylcysteine synthetase gene. Jpn J Cancer Res 1997;88:108-10. [PMID: 9119737 DOI: 10.1111/j.1349-7006.1997.tb00354.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
223 Kang Y, Ju X, Wang L, Ding L, Liu G, Zhang S, Li B. pH and glutathione dual-triggered supramolecular assemblies as synergistic and controlled drug release carriers. Polym Chem 2017;8:7260-70. [DOI: 10.1039/c7py01644a] [Cited by in Crossref: 11] [Article Influence: 2.8] [Reference Citation Analysis]
224 Cerrada-Gimenez M, Pietilä M, Loimas S, Pirinen E, Hyvönen MT, Keinänen TA, Jänne J, Alhonen L. Continuous oxidative stress due to activation of polyamine catabolism accelerates aging and protects against hepatotoxic insults. Transgenic Res 2011;20:387-96. [PMID: 20577801 DOI: 10.1007/s11248-010-9422-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
225 Nagane M, Asai A, Shibui S, Oyama H, Nomura K, Kuchino Y. Expression Pattern of Chemoresistance-related Genes in Human Malignant Brain Tumors: A Working Knowledge for Proper Selection of Anticancer Drugs. Japanese Journal of Clinical Oncology 1999;29:527-34. [DOI: 10.1093/jjco/29.11.527] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
226 Regier MC, Olszewski E, Carter CC, Aitchison JD, Kaushansky A, Davis J, Berthier E, Beebe DJ, Stevens KR. Spatial presentation of biological molecules to cells by localized diffusive transfer. Lab Chip 2019;19:2114-26. [PMID: 31111131 DOI: 10.1039/c9lc00122k] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Isonishi S, Ohkawa K, Tanaka T, Howell SB. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer 2000;82:34-8. [PMID: 10638963 DOI: 10.1054/bjoc.1999.0873] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
228 Cheng X, Xu HD, Ran HH, Liang G, Wu FG. Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy. ACS Nano 2021;15:8039-68. [PMID: 33974797 DOI: 10.1021/acsnano.1c00498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
229 Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010. [PMID: 20811617 DOI: 10.4061/2010/201367] [Cited by in Crossref: 177] [Cited by in F6Publishing: 208] [Article Influence: 16.1] [Reference Citation Analysis]
230 Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 2006;26:10514-23. [PMID: 17035536 DOI: 10.1523/JNEUROSCI.3178-06.2006] [Cited by in Crossref: 211] [Cited by in F6Publishing: 118] [Article Influence: 14.1] [Reference Citation Analysis]
231 Wei X, Shi J, Lin Q, Ma X, Pang Y, Mao H, Li R, Lu W, Wang Y, Liu P. Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway. Front Oncol 2021;11:642229. [PMID: 33816292 DOI: 10.3389/fonc.2021.642229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Dalezis P, Geromichalou E, Polonifi A, Sagredou S, Nikoleousakos N, Nikolaou M, Sarli V, Panayiotidis MI, Trafalis DT. Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma. Cancers (Basel) 2020;12:E1263. [PMID: 32429466 DOI: 10.3390/cancers12051263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Castro ML, Mcconnell MJ, Herst PM. Radiosensitisation by pharmacological ascorbate in glioblastoma multiforme cells, human glial cells, and HUVECs depends on their antioxidant and DNA repair capabilities and is not cancer specific. Free Radical Biology and Medicine 2014;74:200-9. [DOI: 10.1016/j.freeradbiomed.2014.06.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
234 Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43. [PMID: 11406167 DOI: 10.1016/s0027-5107(01)00141-5] [Cited by in Crossref: 577] [Cited by in F6Publishing: 210] [Article Influence: 28.9] [Reference Citation Analysis]
235 Andrews PA. Mechanisms of acquired resistance to cisplatin. In: Goldstein LJ, Ozols RF, editors. Anticancer Drug Resistance. Boston: Springer US; 1994. pp. 217-48. [DOI: 10.1007/978-1-4615-2632-2_11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
236 Samper KG, Marker SC, Bayón P, MacMillan SN, Keresztes I, Palacios Ò, Wilson JJ. Anticancer activity of hydroxy- and sulfonamide-azobenzene platinum(II) complexes in cisplatin-resistant ovarian cancer cells. J Inorg Biochem 2017;174:102-10. [PMID: 28651169 DOI: 10.1016/j.jinorgbio.2017.06.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
237 Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol 2010;65:941-51. [PMID: 19714332 DOI: 10.1007/s00280-009-1101-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
238 McLellan LI, Wolf CR. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat 1999;2:153-64. [PMID: 11504486 DOI: 10.1054/drup.1999.0083] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 3.7] [Reference Citation Analysis]
239 Shi MM, Kugelman A, Iwamoto T, Tian L, Forman HJ. Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells. Journal of Biological Chemistry 1994;269:26512-7. [DOI: 10.1016/s0021-9258(18)47224-9] [Cited by in Crossref: 151] [Article Influence: 5.6] [Reference Citation Analysis]
240 Marxfeld H, Staedtler F, Harleman JH. Characterisation of two rat mammary tumour models for breast cancer research by gene expression profiling. Experimental and Toxicologic Pathology 2006;58:133-43. [DOI: 10.1016/j.etp.2006.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
241 Kielbik M, Szulc-Kielbik I, Nowak M, Sulowska Z, Klink M. Evaluation of nitric oxide donors impact on cisplatin resistance in various ovarian cancer cell lines. Toxicol In Vitro 2016;36:26-37. [PMID: 27427240 DOI: 10.1016/j.tiv.2016.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
242 Ghazal-Aswad S, Hogarth L, Hall AG, George M, Sinha DP, Lind M, Calvert AH, Sunter JP, Newell DR. The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer 1996;74:468-73. [PMID: 8695367 DOI: 10.1038/bjc.1996.384] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
243 Luo K, Guo W, Yu Y, Xu S, Zhou M, Xiang K, Niu K, Zhu X, Zhu G, An Z, Yu Q, Gan Z. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo. J Control Release 2020;326:25-37. [PMID: 32531414 DOI: 10.1016/j.jconrel.2020.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
244 Kürschner G, Zhang Q, Clima R, Xiao Y, Busch JF, Kilic E, Jung K, Berndt N, Bulik S, Holzhütter HG, Gasparre G, Attimonelli M, Babu M, Meierhofer D. Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione. Oncotarget 2017;8:105882-904. [PMID: 29285300 DOI: 10.18632/oncotarget.22413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
245 Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996;271:14981-8. [PMID: 8663001 DOI: 10.1074/jbc.271.25.14981] [Cited by in F6Publishing: 145] [Reference Citation Analysis]
246 Granata A, Nicoletti R, Perego P, Iorio E, Krishnamachary B, Benigni F, Ricci A, Podo F, Bhujwalla ZM, Canevari S, Bagnoli M, Mezzanzanica D. Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget 2015;6:11216-30. [PMID: 25796169 DOI: 10.18632/oncotarget.3589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
247 Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. Journal of Biological Chemistry 1994;269:787-90. [DOI: 10.1016/s0021-9258(17)42175-2] [Cited by in Crossref: 286] [Article Influence: 10.6] [Reference Citation Analysis]
248 Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, Cerny T. Multiple Drug Resistance Parameter Expression in Ovarian Cancer. Gynecologic Oncology 1998;70:176-82. [DOI: 10.1006/gyno.1998.5085] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
249 Ahmed LA, Shehata NI, Abdelkader NF, Khattab MM. Tempol, a superoxide dismutase mimetic agent, ameliorates cisplatin-induced nephrotoxicity through alleviation of mitochondrial dysfunction in mice. PLoS One 2014;9:e108889. [PMID: 25271439 DOI: 10.1371/journal.pone.0108889] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
250 Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity. Gynecologic Oncology 2007;107:S56-71. [DOI: 10.1016/j.ygyno.2007.07.043] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
251 Arnesano F, Natile G. Interference between copper transport systems and platinum drugs. Semin Cancer Biol 2021:S1044-579X(21)00152-8. [PMID: 34058339 DOI: 10.1016/j.semcancer.2021.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.Clin Cancer Res. 2011;17:6206-6217. [PMID: 21844013 DOI: 10.1158/1078-0432.CCR-11-0736] [Cited by in Crossref: 71] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
253 Tani M, Goto S, Kamada K, Mori K, Urata Y, Ihara Y, Kijima H, Ueyama Y, Shibata S, Kondo T. Hammerhead ribozyme against gamma-glutamylcysteine synthetase attenuates resistance to ionizing radiation and cisplatin in human T98G glioblastoma cells. Jpn J Cancer Res 2002;93:716-22. [PMID: 12079521 DOI: 10.1111/j.1349-7006.2002.tb01311.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
254 Bailey HH. l-S,R-buthionine sulfoximine: historical development and clinical issues. Chemico-Biological Interactions 1998;111-112:239-54. [DOI: 10.1016/s0009-2797(97)00164-6] [Cited by in Crossref: 114] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
255 Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB j 1999;13:1169-83. [DOI: 10.1096/fasebj.13.10.1169] [Cited by in Crossref: 573] [Cited by in F6Publishing: 394] [Article Influence: 26.0] [Reference Citation Analysis]
256 Hu X, Legler PM, Khavrutskii I, Scorpio A, Compton JR, Robertson KL, Friedlander AM, Wallqvist A. Probing the donor and acceptor substrate specificity of the γ-glutamyl transpeptidase. Biochemistry 2012;51:1199-212. [PMID: 22257032 DOI: 10.1021/bi200987b] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
257 Ranganathan S, Walsh E, Godwin A, Tew K. Cloning and characterization of human colon glyoxalase-I. Journal of Biological Chemistry 1993;268:5661-7. [DOI: 10.1016/s0021-9258(18)53370-6] [Cited by in Crossref: 46] [Article Influence: 1.6] [Reference Citation Analysis]
258 Zayed A, Shoeib T, Taylor SE, Jones GD, Thomas AL, Wood JP, Reid HJ, Sharp BL. Determination of Pt–DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry. International Journal of Mass Spectrometry 2011;307:70-8. [DOI: 10.1016/j.ijms.2010.11.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
259 Hagrman D, Goodisman J, Dabrowiak JC, Souid A. KINETIC STUDY ON THE REACTION OF CISPLATIN WITH METALLOTHIONEIN. Drug Metab Dispos 2003;31:916-23. [DOI: 10.1124/dmd.31.7.916] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 4.2] [Reference Citation Analysis]
260 Wang S, Higgins VJ, Aldrich-Wright JR, Wu MJ. Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator. J Chem Biol 2012;5:51-61. [PMID: 23226166 DOI: 10.1007/s12154-011-0070-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
261 Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma. Chem Biol Interact 1998;111-112:277-305. [PMID: 9679561 DOI: 10.1016/s0009-2797(97)00167-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
262 Lynn RC, Poussin M, Kalota A, Feng Y, Low PS, Dimitrov DS, Powell DJ Jr. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood 2015;125:3466-76. [PMID: 25887778 DOI: 10.1182/blood-2014-11-612721] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 15.7] [Reference Citation Analysis]
263 Rizzo A, Napoli A, Roggiani F, Tomassetti A, Bagnoli M, Mezzanzanica D. One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer. Int J Mol Sci 2018;19:E2092. [PMID: 30029471 DOI: 10.3390/ijms19072092] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
264 Palmirotta R, Carella C, Silvestris E, Cives M, Stucci SL, Tucci M, Lovero D, Silvestris F. SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget 2018;9:25355-82. [PMID: 29861877 DOI: 10.18632/oncotarget.25256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
265 Vincenzini MT, Marraccini P, Iantomasi T, Favilli F, Pacini S, Ruggiero M. Altered metabolism of glutathione in cells transformed by oncogenes which cause resistance to ionizing radiations. FEBS Letters 1993;320:219-23. [DOI: 10.1016/0014-5793(93)80590-q] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
266 Hofmann NA, Yang J, Trauger SA, Nakayama H, Huang L, Strunk D, Moses MA, Klagsbrun M, Bischoff J, Graier WF. The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis. Br J Pharmacol 2015;172:4107-18. [PMID: 25989290 DOI: 10.1111/bph.13196] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
267 Roudier E, Bachelet C, Perrin A. Pyruvate reduces DNA damage during hypoxia and after reoxygenation in hepatocellular carcinoma cells. FEBS J 2007;274:5188-98. [PMID: 17868379 DOI: 10.1111/j.1742-4658.2007.06044.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
268 Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997;65:130-7. [PMID: 9103402 DOI: 10.1006/gyno.1996.4609] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
269 McEvoy LM, O'Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, Blackshields G, Sheils O, O'Leary JJ. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer 2015;15:547. [PMID: 26205780 DOI: 10.1186/s12885-015-1539-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
270 Ikeda Y, Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Methods Enzymol. 2005;401:408-425. [PMID: 16399400 DOI: 10.1016/S0076-6879(05)01025-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
271 Myungjin Lee J, Mhawech-fauceglia P, Lee N, Cristina Parsanian L, Gail Lin Y, Andrew Gayther S, Lawrenson K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 2013;93:528-42. [DOI: 10.1038/labinvest.2013.41] [Cited by in Crossref: 187] [Cited by in F6Publishing: 175] [Article Influence: 23.4] [Reference Citation Analysis]
272 Olsen PM, Ruiz C, Lussier D, Le BK, Angel N, Smith M, Hwang C(, Khatib R, Jenkins J, Adams K, Getcher J, Tham F, Chen Z(, Wilson EH, Eichler JF. Synthesis, characterization, and antitumor activity of unusual pseudo five coordinate gold(III) complexes: Distinct cytotoxic mechanism or expensive ligand delivery systems? Journal of Inorganic Biochemistry 2014;141:121-31. [DOI: 10.1016/j.jinorgbio.2014.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
273 Liu Y, Ouyang Q, Sun Z, Tan J, Huang W, Liu J, Liu Z, Zhou H, Zeng F, Liu Y. The Novel Zinc Finger Protein 587B Gene, ZNF587B, Regulates Cell Proliferation and Metastasis in Ovarian Cancer Cells in vivo and in vitro. Cancer Manag Res 2020;12:5119-30. [PMID: 32617020 DOI: 10.2147/CMAR.S252347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Raghavan R, Hyter S, Pathak HB, Godwin AK, Konecny G, Wang C, Goode EL, Fridley BL. Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer. BMC Genomics 2016;17:811. [PMID: 27756228 DOI: 10.1186/s12864-016-3149-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
275 Nicco C, Laurent A, Chereau C, Weill B, Batteux F. Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed Pharmacother 2005;59:169-74. [PMID: 15862711 DOI: 10.1016/j.biopha.2005.03.009] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
276 Li Q, Tsang B, Bostick-Bruton F, Reed E. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 1999;57:347-53. [PMID: 9933022 DOI: 10.1016/s0006-2952(98)00291-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
277 Chen D, Bobko AA, Gross AC, Evans R, Marsh CB, Khramtsov VV, Eubank TD, Friedman A. Involvement of tumor macrophage HIFs in chemotherapy effectiveness: mathematical modeling of oxygen, pH, and glutathione. PLoS One 2014;9:e107511. [PMID: 25295611 DOI: 10.1371/journal.pone.0107511] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
278 Miyahara Y, Ikeda S, Muroya T, Yasuoka C, Urata Y, Horiuchi S, Kohno S, Kondo T. Nepsilon-(Carboxymethyl)lysine induces gamma-glutamylcysteine synthetase in RAW264.7 cells. Biochem Biophys Res Commun 2002;296:32-40. [PMID: 12147223 DOI: 10.1016/s0006-291x(02)00816-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
279 Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008;99:1218-1226. [PMID: 18429963 DOI: 10.1111/j.1349-7006.2008.00793.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
280 Yamaguchi H, Kidachi Y, Kamiie K, Noshita T, Umetsu H, Fuke Y, Ryoyama K. Utilization of 6-(methylsulfinyl)hexyl isothiocyanate for sensitization of tumor cells to antitumor agents in combination therapies. Biochemical Pharmacology 2013;86:458-68. [DOI: 10.1016/j.bcp.2013.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
281 Griffith OW, Mulcahy RT. The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol 1999;73:209-67, xii. [PMID: 10218110 DOI: 10.1002/9780470123195.ch7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 109] [Article Influence: 3.1] [Reference Citation Analysis]
282 Khalifa AM, Elsheikh MA, Khalifa AM, Elnaggar YSR. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. J Control Release 2019;311-312:125-37. [PMID: 31476342 DOI: 10.1016/j.jconrel.2019.08.034] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
283 Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61. [PMID: 20547991 DOI: 10.1200/JCO.2009.27.5719] [Cited by in Crossref: 330] [Cited by in F6Publishing: 177] [Article Influence: 30.0] [Reference Citation Analysis]
284 Fujigaki S, Nishiumi S, Kobayashi T, Suzuki M, Iemoto T, Kojima T, Ito Y, Daiko H, Kato K, Shouji H, Honda K, Azuma T, Yoshida M. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomark Med. 2018;12:827-840. [PMID: 30043633 DOI: 10.2217/bmm-2017-0449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
285 Soh Y, Goto S, Kitajima M, Moriyama S, Kotera K, Nakayama T, Nakajima H, Kondo T, Ishimaru T. Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers. Clin Oncol (R Coll Radiol). 2005;17:264-270. [PMID: 15997922 DOI: 10.1016/j.clon.2004.11.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
286 Sun WM, Huang ZZ, Lu SC. Regulation of gamma-glutamylcysteine synthetase by protein phosphorylation. Biochem J 1996;320 ( Pt 1):321-8. [PMID: 8947504 DOI: 10.1042/bj3200321] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 3.4] [Reference Citation Analysis]
287 Wang Y, Jacobs EJ, Carter BD, Gapstur SM, Stevens VL. Plasma Metabolomic Profiles and Risk of Advanced and Fatal Prostate Cancer. Eur Urol Oncol 2021;4:56-65. [PMID: 31378665 DOI: 10.1016/j.euo.2019.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
288 Marrache S, Pathak RK, Dhar S. Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc Natl Acad Sci U S A 2014;111:10444-9. [PMID: 25002500 DOI: 10.1073/pnas.1405244111] [Cited by in Crossref: 150] [Cited by in F6Publishing: 146] [Article Influence: 21.4] [Reference Citation Analysis]
289 Hirata J, Kikuchi Y, Kita T, Imaizumi E, Tode T, Ishii K, Kudoh K, Nagata I. Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine. Int J Cancer 1993;55:521-7. [PMID: 8375936 DOI: 10.1002/ijc.2910550332] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
290 Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 2004;91:270-6. [PMID: 15199393 DOI: 10.1038/sj.bjc.6601956] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
291 Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223-42. [PMID: 18986801 DOI: 10.1016/j.etp.2008.09.003] [Cited by in Crossref: 323] [Cited by in F6Publishing: 295] [Article Influence: 24.8] [Reference Citation Analysis]
292 Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecol Oncol 2018;149:155-62. [PMID: 29402501 DOI: 10.1016/j.ygyno.2018.01.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
293 Tanaka T, Uchiumi T, Kohno K, Tomonari A, Nishio K, Saijo N, Kondo T, Kuwano M. Glutathione homeostasis in human hepatic cells: overexpression of gamma-glutamylcysteine synthetase gene in cell lines resistant to buthionine sulfoximine, an inhibitor of glutathione synthesis. Biochem Biophys Res Commun 1998;246:398-403. [PMID: 9610371 DOI: 10.1006/bbrc.1998.8631] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
294 Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:76-82. [PMID: 17291235 DOI: 10.1111/j.1525-1438.2006.00752.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
295 Oien DB, Moskovitz J. Genetic regulation of longevity and age-associated diseases through the methionine sulfoxide reductase system. Biochim Biophys Acta Mol Basis Dis 2019;1865:1756-62. [PMID: 30481589 DOI: 10.1016/j.bbadis.2018.11.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
296 Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol 2006;101:507-19. [PMID: 16387351 DOI: 10.1016/j.ygyno.2005.11.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
297 Yokomizo A, Kohno K, Wada M, Ono M, Morrow CS, Cowan KH, Kuwano M. Markedly Decreased Expression of Glutathione S-Transferase π Gene in Human Cancer Cell Lines Resistant to Buthionine Sulfoximine, an Inhibitor of Cellular Glutathione Synthesis. Journal of Biological Chemistry 1995;270:19451-7. [DOI: 10.1074/jbc.270.33.19451] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis]
298 Noé JE. L-Glutamine Use in the Treatment and Prevention of Mucositis and Cachexia: A Naturopathic Perspective. Integr Cancer Ther 2009;8:409-15. [DOI: 10.1177/1534735409348865] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
299 Oehlsen ME, Qu Y, Farrell N. Reaction of Polynuclear Platinum Antitumor Compounds with Reduced Glutathione Studied by Multinuclear ( 1 H, 1 H− 15 N Gradient Heteronuclear Single-Quantum Coherence, and 195 Pt) NMR Spectroscopy. Inorg Chem 2003;42:5498-506. [DOI: 10.1021/ic030045b] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 4.3] [Reference Citation Analysis]
300 Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione Depletion Induced by c-Myc Downregulation Triggers Apoptosis on Treatment with Alkylating Agents. Neoplasia 2004;6:195-206. [DOI: 10.1593/neo.03370] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
301 Rink L, Ochs MF, Zhou Y, von Mehren M, Godwin AK. ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One 2013;8:e54477. [PMID: 23372733 DOI: 10.1371/journal.pone.0054477] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
302 Li L, Shi W, Wu X, Gong Q, Li X, Ma H. Monitoring γ-glutamyl transpeptidase activity and evaluating its inhibitors by a water-soluble near-infrared fluorescent probe. Biosensors and Bioelectronics 2016;81:395-400. [DOI: 10.1016/j.bios.2016.03.021] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 13.2] [Reference Citation Analysis]
303 Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 2007;42:872-81. [PMID: 17320769 DOI: 10.1016/j.freeradbiomed.2006.12.021] [Cited by in Crossref: 285] [Cited by in F6Publishing: 267] [Article Influence: 19.0] [Reference Citation Analysis]
304 Giaccone G. Clinical Perspectives on Platinum Resistance: . Drugs 2000;59:9-17. [DOI: 10.2165/00003495-200059004-00002] [Cited by in Crossref: 227] [Cited by in F6Publishing: 222] [Article Influence: 10.8] [Reference Citation Analysis]
305 Wender PA, Galliher WC, Bhat NM, Pillow TH, Bieber MM, Teng NN. Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol 2012;126:118-23. [PMID: 22484398 DOI: 10.1016/j.ygyno.2012.03.049] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
306 Shoeib T, Sharp BL. Interactions of oxaliplatin with the cytoplasmic thiol containing ligand glutathione. Metallomics 2012;4:1308. [DOI: 10.1039/c2mt20127e] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
307 Pich A, Rancourt C. A role for intracellular immunization in chemosensitization of tumor cells? Gene Ther 1999;6:1202-9. [PMID: 10455428 DOI: 10.1038/sj.gt.3300952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
308 Gibson D. The mechanism of action of platinum anticancer agents—what do we really know about it? Dalton Trans 2009. [DOI: 10.1039/b918871c] [Cited by in Crossref: 143] [Cited by in F6Publishing: 133] [Article Influence: 11.9] [Reference Citation Analysis]
309 Natarajan SK, Venneti S. Glutamine Metabolism in Brain Tumors. Cancers (Basel) 2019;11:E1628. [PMID: 31652923 DOI: 10.3390/cancers11111628] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
310 Busschots S, O'Toole S, O'Leary JJ, Stordal B. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Exp Cell Res 2015;336:1-14. [PMID: 25499884 DOI: 10.1016/j.yexcr.2014.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
311 Palmer AM, Peña B, Sears RB, Chen O, El Ojaimi M, Thummel RP, Dunbar KR, Turro C. Cytotoxicity of cyclometallated ruthenium complexes: the role of ligand exchange on the activity. Philos Trans A Math Phys Eng Sci 2013;371:20120135. [PMID: 23776296 DOI: 10.1098/rsta.2012.0135] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
312 Morin M, Rivard C, Keillor JW. γ-Glutamyl transpeptidase acylation with peptidic substrates: free energy relationships measured by an HPLC kinetic assay. Org Biomol Chem 2006;4:3790-801. [DOI: 10.1039/b606914b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
313 Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer. 1995;71:676-683. [PMID: 7710928 DOI: 10.1038/bjc.1995.134] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 2.6] [Reference Citation Analysis]
314 Zhang SQ, Yung KK, Chung SK, Chung SS. Aldo-keto reductases-mediated cytotoxicity of 2-deoxyglucose: A novel anticancer mechanism. Cancer Sci 2018;109:1970-80. [PMID: 29617059 DOI: 10.1111/cas.13604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
315 Zhao J, Gou S, Liu F, Sun Y, Gao C. Anticancer Potency of Platinum(II) Complexes Containing Both Chloride Anion and Chelated Carboxylate as Leaving Groups. Inorg Chem 2013;52:8163-70. [DOI: 10.1021/ic400907t] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
316 Liao L, Liu J, Dreaden EC, Morton SW, Shopsowitz KE, Hammond PT, Johnson JA. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc 2014;136:5896-9. [PMID: 24724706 DOI: 10.1021/ja502011g] [Cited by in Crossref: 261] [Cited by in F6Publishing: 225] [Article Influence: 37.3] [Reference Citation Analysis]
317 Jendželovský R, Jendželovská Z, Hiľovská L, Kovaľ J, Mikeš J, Fedoročko P. Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin. Toxicol Lett 2016;243:56-66. [PMID: 26721606 DOI: 10.1016/j.toxlet.2015.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
318 Raghunathan K, Ahsan A, Ray D, Nyati MK, Veatch SL. Membrane Transition Temperature Determines Cisplatin Response. PLoS One 2015;10:e0140925. [PMID: 26484687 DOI: 10.1371/journal.pone.0140925] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
319 Los G, Muggia FM. Platinum Resistance: Experimental and Clinical Status. Hematology/Oncology Clinics of North America 1994;8:411-29. [DOI: 10.1016/s0889-8588(18)30179-5] [Cited by in Crossref: 13] [Article Influence: 0.5] [Reference Citation Analysis]
320 Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y, Nimmannit U. Curcumin Sensitizes Lung Cancer Cells to Cisplatin-Induced Apoptosis Through Superoxide Anion-Mediated Bcl-2 Degradation. Cancer Investigation 2009;27:624-35. [DOI: 10.1080/07357900802653472] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
321 Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 2001;93:725-30. [PMID: 11477586 DOI: 10.1002/ijc.1392] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
322 Calvert P, Yao KS, Hamilton TC, O'Dwyer PJ. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998;111-112:213-24. [PMID: 9679556 DOI: 10.1016/s0009-2797(98)00008-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
323 Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9-23. [PMID: 17084534 DOI: 10.1016/j.ctrv.2006.09.006] [Cited by in Crossref: 1013] [Cited by in F6Publishing: 922] [Article Influence: 67.5] [Reference Citation Analysis]
324 Yang X, Yu Y, Huang X, Chen Q, Wu H, Wang R, Qi R, Miao Y, Qiu Y. Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance. Materials Science and Engineering: C 2019;96:96-104. [DOI: 10.1016/j.msec.2018.10.092] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
325 Song W, Tang Z, Shen N, Yu H, Jia Y, Zhang D, Jiang J, He C, Tian H, Chen X. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. Journal of Controlled Release 2016;231:94-102. [DOI: 10.1016/j.jconrel.2016.02.039] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
326 Hochwald SN, Rose DM, Brennan MF, Burt ME. Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma. Ann Surg Oncol 1997;4:303-9. [PMID: 9181229 DOI: 10.1007/BF02303579] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
327 Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996;65:479-84. [DOI: 10.1002/(sici)1097-0215(19960208)65:4<479::aid-ijc15>3.0.co;2-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
328 Han L, Hiratake J, Tachi N, Suzuki H, Kumagai H, Sakata K. Gamma-(monophenyl)phosphono glutamate analogues as mechanism-based inhibitors of gamma-glutamyl transpeptidase. Bioorg Med Chem 2006;14:6043-54. [PMID: 16716594 DOI: 10.1016/j.bmc.2006.05.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
329 Marverti G, Monti MG, Bettuzzi S, Caporali A, Astancolle S, Moruzzi MS. Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine N(1)-acetyltransferase expression. Int J Biochem Cell Biol 2004;36:123-37. [PMID: 14592538 DOI: 10.1016/s1357-2725(03)00174-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
330 Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 2000;29:219-28. [DOI: 10.1002/1098-2744(200012)29:4<219::aid-mc1004>3.0.co;2-d] [Cited by in Crossref: 55] [Article Influence: 2.8] [Reference Citation Analysis]
331 Maxwell T, Banu T, Price E, Tharkur J, Campos MG, Gesquiere A, Santra S. Non-Cytotoxic Quantum Dot-Chitosan Nanogel Biosensing Probe for Potential Cancer Targeting Agent. Nanomaterials (Basel) 2015;5:2359-79. [PMID: 28347126 DOI: 10.3390/nano5042359] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
332 Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. GlutathioneS-transferase-? expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997;79:521-7. [DOI: 10.1002/(sici)1097-0142(19970201)79:3<521::aid-cncr14>3.0.co;2-5] [Cited by in Crossref: 41] [Article Influence: 1.7] [Reference Citation Analysis]
333 Paolicchi A, Sotiropuolou M, Perego P, Daubeuf S, Visvikis A, Lorenzini E, Franzini M, Romiti N, Chieli E, Leone R, Apostoli P, Colangelo D, Zunino F, Pompella A. gamma-Glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney. Eur J Cancer 2003;39:996-1003. [PMID: 12706370 DOI: 10.1016/s0959-8049(03)00067-4] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
334 Durham JR, Frierson HF, Hanigan MH. Gamma-glutamyl transpeptidase immunoreactivity in benign and malignant breast tissue. Breast Cancer Res Treat 1997;45:55-62. [DOI: 10.1023/a:1005889006557] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
335 Soldatović T, Bugarcić ZD. Study of the reactions between platinum(II) complexes and L-methionine in the presence and absence of 5'-GMP. J Inorg Biochem 2005;99:1472-9. [PMID: 15927265 DOI: 10.1016/j.jinorgbio.2005.04.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
336 Chang HP, Liang WC, Lyu RC, Chi MC, Wang TF, Su KL, Hung HC, Lin LL. Effects of C-terminal truncation on autocatalytic processing of Bacillus licheniformis gamma-glutamyl transpeptidase. Biochemistry (Mosc) 2010;75:919-29. [PMID: 20673217 DOI: 10.1134/s0006297910070151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
337 New EJ, Duan R, Zhang JZ, Hambley TW. Investigations using fluorescent ligands to monitor platinum(iv) reduction and platinum(ii) reactions in cancer cells. Dalton Trans 2009. [DOI: 10.1039/b821603g] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
338 Assis J, Pereira C, Nogueira A, Pereira D, Carreira R, Medeiros R. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis. Cancer Treat Rev 2017;61:35-52. [PMID: 29100168 DOI: 10.1016/j.ctrv.2017.10.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
339 Yazlovitskaya EM, DeHaan RD, Persons DL. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 2001;283:732-7. [PMID: 11350044 DOI: 10.1006/bbrc.2001.4849] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
340 Wambecke A, Ahmad M, Lambert B, Joly F, Poulain L, Denoyelle C, Meryet-Figuiere M. The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer. Gynecol Oncol. 2020;156:726-733. [PMID: 31883617 DOI: 10.1016/j.ygyno.2019.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
341 Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev. 1999;99:2467-2498. [PMID: 11749487 DOI: 10.1021/cr980421n] [Cited by in Crossref: 2131] [Cited by in F6Publishing: 1995] [Article Influence: 96.9] [Reference Citation Analysis]
342 Kasherman Y, Sturup S, Gibson D. Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts. J Med Chem 2009;52:4319-28. [PMID: 19537717 DOI: 10.1021/jm900138u] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 7.4] [Reference Citation Analysis]
343 Cho S, Hazama M, Urata Y, Goto S, Horiuchi S, Sumikawa K, Kondo T. Protective role of glutathione synthesis in response to oxidized low density lipoprotein in human vascular endothelial cells. Free Radical Biology and Medicine 1999;26:589-602. [DOI: 10.1016/s0891-5849(98)00232-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
344 Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr. High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 2016;30:1355-64. [PMID: 26898190 DOI: 10.1038/leu.2016.35] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 11.6] [Reference Citation Analysis]
345 Sinha S, Pal K, Elkhanany A, Dutta S, Cao Y, Mondal G, Iyer S, Somasundaram V, Couch FJ, Shridhar V, Bhattacharya R, Mukhopadhyay D, Srinivas P. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer 2013;132:1201-12. [PMID: 22806981 DOI: 10.1002/ijc.27724] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
346 Pompella A, Corti A, Paolicchi A, Giommarelli C, Zunino F. Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol. 2007;7:360-366. [PMID: 17613273 DOI: 10.1016/j.coph.2007.04.004] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 7.5] [Reference Citation Analysis]
347 Nishii Y, Morishima M, Kakehi Y, Umehara K, Kioka N, Terano Y, Amachi T, Ueda K. CROP/Luc7A, a novel serine/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line. FEBS Lett 2000;465:153-6. [PMID: 10631324 DOI: 10.1016/s0014-5793(99)01744-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
348 Lazo JS. Metals and Anticancer Drug Resistance. In: Goyer RA, Cherian MG, editors. Toxicology of Metals. Berlin: Springer Berlin Heidelberg; 1995. pp. 267-78. [DOI: 10.1007/978-3-642-79162-8_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
349 Oien DB, Chien J, Cheng N. Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway. Transl Cancer Res 2016;5:S514-9. [PMID: 30542639 DOI: 10.21037/tcr.2016.09.32] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
350 Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830:3143-3153. [PMID: 22995213 DOI: 10.1016/j.bbagen.2012.09.008] [Cited by in Crossref: 825] [Cited by in F6Publishing: 768] [Article Influence: 91.7] [Reference Citation Analysis]
351 Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 2009;47:1619-31. [PMID: 19751820 DOI: 10.1016/j.freeradbiomed.2009.09.006] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
352 Vijayalakshmi B, Sesikeran B, Udaykumar P, Kalyanasundaram S, Raghunath M. Chronic low vitamin intake potentiates cisplatin-induced intestinal epithelial cell apoptosis in WNIN rats. World J Gastroenterol 2006; 12(7): 1078-1085 [PMID: 16534849 DOI: 10.3748/wjg.v12.i7.1078] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
353 Lage H, Denkert C. Resistance to Chemotherapy in Ovarian Carcinoma. In: Dietel M, editor. Targeted Therapies in Cancer. Berlin: Springer Berlin Heidelberg; 2007. pp. 51-60. [DOI: 10.1007/978-3-540-46091-6_6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
354 Chen Z, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, Saijo N, Kondo T, Akiyama S. An Active Efflux System for Heavy Metals in Cisplatin-Resistant Human KB Carcinoma Cells. Experimental Cell Research 1998;240:312-20. [DOI: 10.1006/excr.1998.3938] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
355 Cannazza G, Cazzato AS, Marraccini C, Pavesi G, Pirondi S, Guerrini R, Pelà M, Frassineti C, Ferrari S, Marverti G, Ponterini G, Costi MP. Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells. J Med Chem 2014;57:10551-6. [PMID: 25353379 DOI: 10.1021/jm501397h] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
356 Arnesano F, Nardella MI, Natile G. Platinum drugs, copper transporters and copper chelators. Coordination Chemistry Reviews 2018;374:254-60. [DOI: 10.1016/j.ccr.2018.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
357 Zheng C, Han L, Wu S. A metabolic investigation of anticancer effect of G. glabra root extract on nasopharyngeal carcinoma cell line, C666-1. Mol Biol Rep 2019;46:3857-64. [DOI: 10.1007/s11033-019-04828-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
358 Saxena M, Delgado Y, Sharma RK, Sharma S, Guzmán SLPL, Tinoco AD, Griebenow K. Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome c via a transferrin conjugate. PLoS One 2018;13:e0195542. [PMID: 29649293 DOI: 10.1371/journal.pone.0195542] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
359 Huang ZZ, Chen C, Zeng Z, Yang H, Oh J, Chen L, Lu SC. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J 2001;15:19-21. [PMID: 11099488 DOI: 10.1096/fj.00-0445fje] [Cited by in Crossref: 129] [Cited by in F6Publishing: 126] [Article Influence: 6.1] [Reference Citation Analysis]
360 Chen W, Lian W, Yuan Y, Li M. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis 2019;10:600. [PMID: 31395855 DOI: 10.1038/s41419-019-1824-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
361 Marker SC, King AP, Swanda RV, Vaughn B, Boros E, Qian SB, Wilson JJ. Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes. Angew Chem Int Ed Engl 2020;59:13391-400. [PMID: 32396709 DOI: 10.1002/anie.202004883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
362 Cao ZT, Chen ZY, Sun CY, Li HJ, Wang HX, Cheng QQ, Zuo ZQ, Wang JL, Liu YZ, Wang YC, Wang J. Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles. Biomaterials 2016;94:9-19. [PMID: 27088406 DOI: 10.1016/j.biomaterials.2016.04.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
363 Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J. Enhanced Expression of gamma/Glutamylcysteine Synthetase and Glutathione S-transferase Genes in Cisplatin-Resistant Bladder Cancer Cells with Multidrug Resistance Phenotype. Journal of Urology 1997;157:1054-8. [DOI: 10.1016/s0022-5347(01)65140-1] [Cited by in Crossref: 27] [Article Influence: 1.1] [Reference Citation Analysis]
364 Høgh RI, Droujinine A, Møller SH, Jepsen SD, Mellergaard M, Andresen L, Skov S. Fumarate Upregulates Surface Expression of ULBP2/ULBP5 by Scavenging Glutathione Antioxidant Capacity. J Immunol 2020;204:1746-59. [PMID: 32144161 DOI: 10.4049/jimmunol.1900740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, Ohnishi N, Yokoyama T. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother Pharmacol 2006;58:785-93. [PMID: 16534613 DOI: 10.1007/s00280-006-0226-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
366 Ling X, Tu J, Wang J, Shajii A, Kong N, Feng C, Zhang Y, Yu M, Xie T, Bharwani Z, Aljaeid BM, Shi B, Tao W, Farokhzad OC. Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy. ACS Nano 2019;13:357-70. [PMID: 30485068 DOI: 10.1021/acsnano.8b06400] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 34.0] [Reference Citation Analysis]
367 Nunes SC, Serpa J. Glutathione in Ovarian Cancer: A Double-Edged Sword. Int J Mol Sci 2018;19:E1882. [PMID: 29949936 DOI: 10.3390/ijms19071882] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
368 Zhang H, Gou S, Zhao J, Chen F, Xu G, Liu X. Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N(1),N(2)-dibutyl-1,2-diaminocyclohexane. Eur J Med Chem 2015;96:187-95. [PMID: 25874342 DOI: 10.1016/j.ejmech.2015.04.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
369 Bhatt M, Ivan C, Xie X, Siddik ZH. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget 2017;8:10905-18. [PMID: 28038466 DOI: 10.18632/oncotarget.14228] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
370 Ikeda K, Miura K, Himeno S, Imura N, Naganuma A. Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Mol Cell Biochem 2001;219:51-6. [PMID: 11354253 DOI: 10.1023/a:1011083429704] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
371 Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase ?, heat shock protein 27, and lung resistance-related protein) in osteosarcoma: Relationship with poor prognosis. Cancer 1997;79:2336-44. [DOI: 10.1002/(sici)1097-0142(19970615)79:12<2336::aid-cncr7>3.0.co;2-j] [Cited by in Crossref: 79] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
372 Iida T, Mori E, Mori K, Goto S, Urata Y, Oka M, Kohno S, Kondo T. Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int J Cancer 1999;82:405-11. [PMID: 10399958 DOI: 10.1002/(sici)1097-0215(19990730)82:3<405::aid-ijc14>3.0.co;2-m] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
373 Valashedi MR, Najafi-Ghalehlou N, Nikoo A, Bamshad C, Tomita K, Kuwahara Y, Sato T, Roushandeh AM, Roudkenar MH. Cashing in on ferroptosis against tumor cells: Usher in the next chapter. Life Sci 2021;285:119958. [PMID: 34534562 DOI: 10.1016/j.lfs.2021.119958] [Reference Citation Analysis]
374 Wong DL, Zhang A, Faponle AS, de Visser SP, Stillman MJ. Glutathione binding to dirhodium tetraacetate: a spectroscopic, mass spectral and computational study of an anti-tumour compound. Metallomics 2017;9:501-16. [PMID: 28474044 DOI: 10.1039/c7mt00040e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
375 Daubeuf S, Balin D, Leroy P, Visvikis A. Different mechanisms for γ-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochemical Pharmacology 2003;66:595-604. [DOI: 10.1016/s0006-2952(03)00343-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
376 To KK, Au-Yeung SC, Ho YP. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anticancer Drugs 2006;17:673-83. [PMID: 16917213 DOI: 10.1097/01.cad.0000217421.14090.e0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
377 Liu M, Zhang X, Hu CF, Xu Q, Zhu HX, Xu NZ. MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells. Chin J Cancer 2014;33:285-94. [PMID: 24589211 DOI: 10.5732/cjc.013.10136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
378 Li QQ, Lee RX, Liang H, Wang G, Li JM, Zhong Y, Reed E. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol 2013;43:721-8. [PMID: 23817665 DOI: 10.3892/ijo.2013.1996] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
379 Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86:171-176. [PMID: 12144824 DOI: 10.1006/gyno.2002.6738] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
380 Bose RN, Moghaddas S, Belkacemi L, Tripathi S, Adams NR, Majmudar P, McCall K, Dezvareh H, Nislow C. Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications To Treat Resistant Cancers. J Med Chem. 2015;58:8387-8401. [PMID: 26455832 DOI: 10.1021/acs.jmedchem.5b00732] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
381 Vincent BRDS, Mousset S, Jacquemin-sablon A. Cysteine control over glutathione homeostasis in Chinese hamster fibroblasts overexpressing a gamma-glutamylcysteine synthetase activity. Eur J Biochem 1999;262:873-8. [DOI: 10.1046/j.1432-1327.1999.00449.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
382 Scuto M, Trovato Salinaro A, Caligiuri I, Ontario ML, Greco V, Sciuto N, Crea R, Calabrese EJ, Rizzolio F, Canzonieri V, Calabrese V. Redox modulation of vitagenes via plant polyphenols and vitamin D: Novel insights for chemoprevention and therapeutic interventions based on organoid technology. Mech Ageing Dev 2021;199:111551. [PMID: 34358533 DOI: 10.1016/j.mad.2021.111551] [Reference Citation Analysis]
383 Paolicchi A, Lorenzini E, Perego P, Supino R, Zunino F, Comporti M, Pompella A. Extra-cellular thiol metabolism in clones of human metastatic melanoma with different gamma-glutamyl transpeptidase expression: Implications for cell response to platinum-based drugs. Int J Cancer 2002;97:740-5. [DOI: 10.1002/ijc.10110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
384 Comess KM, Lippard SJ. Molecular Aspects of Platinum-DNA Interactions. In: Neidle S, Waring MJ, editors. Molecular Aspects of Anticancer Drug-DNA Interactions. London: Macmillan Education UK; 1993. pp. 134-68. [DOI: 10.1007/978-1-349-12356-8_5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
385 Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, Pathak C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken) 2020;:e1291. [PMID: 33052041 DOI: 10.1002/cnr2.1291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
386 Brouwer M, Hoexum-Brouwer T, Cashon RE. A putative glutathione-binding site in CdZn-metallothionein identified by equilibrium binding and molecular-modelling studies. Biochem J 1993;294 ( Pt 1):219-25. [PMID: 8363576 DOI: 10.1042/bj2940219] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 1.9] [Reference Citation Analysis]
387 Chen HH, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010;2010:430939. [PMID: 20885916 DOI: 10.1155/2010/430939] [Cited by in Crossref: 127] [Cited by in F6Publishing: 129] [Article Influence: 11.5] [Reference Citation Analysis]
388 Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913. [PMID: 23766865 DOI: 10.1155/2013/972913] [Cited by in Crossref: 506] [Cited by in F6Publishing: 479] [Article Influence: 63.3] [Reference Citation Analysis]
389 Al-Eisawi Z, Beale P, Chan C, Yu JQ, Proschogo N, Molloy M, Huq F. Changes in the in vitro activity of platinum drugs when administered in two aliquots. BMC Cancer 2016;16:688. [PMID: 27566066 DOI: 10.1186/s12885-016-2731-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
390 Smith ER, Cai KQ, Smedberg JL, Ribeiro MM, Rula ME, Slater C, Godwin AK, Xu XX. Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells. PLoS One 2010;5:e9295. [PMID: 20174585 DOI: 10.1371/journal.pone.0009295] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
391 Benassi B, Zupi G, Biroccio A. γ-Glutamylcysteine Synthetase Mediates the c-Myc-Dependent Response to Antineoplastic Agents in Melanoma Cells. Mol Pharmacol 2007;72:1015-23. [DOI: 10.1124/mol.107.038687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
392 Rebrin I, Forster MJ, Sohal RS. Association between life-span extension by caloric restriction and thiol redox state in two different strains of mice. Free Radic Biol Med 2011;51:225-33. [PMID: 21530646 DOI: 10.1016/j.freeradbiomed.2011.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
393 Ishikawa T, Ali-osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. Journal of Biological Chemistry 1993;268:20116-25. [DOI: 10.1016/s0021-9258(20)80702-9] [Cited by in Crossref: 209] [Article Influence: 7.5] [Reference Citation Analysis]
394 Huynh VT, Quek JY, de Souza PL, Stenzel MH. Block Copolymer Micelles with Pendant Bifunctional Chelator for Platinum Drugs: Effect of Spacer Length on the Viability of Tumor Cells. Biomacromolecules 2012;13:1010-23. [DOI: 10.1021/bm2017299] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 7.2] [Reference Citation Analysis]
395 Perego P, Paolicchi A, Tongiani R, Pompella A, Tonarelli P, Carenini N, Romanelli S, Zunino F. The cell-specific anti-proliferative effect of reduced glutathione is mediated by γ-glutamyl transpeptidase-dependent extracellular pro-oxidant reactions. Int J Cancer 1997;71:246-50. [DOI: 10.1002/(sici)1097-0215(19970410)71:2<246::aid-ijc20>3.0.co;2-e] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
396 Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene 2014;33:3619-33. [PMID: 23934194 DOI: 10.1038/onc.2013.321] [Cited by in Crossref: 122] [Cited by in F6Publishing: 119] [Article Influence: 15.3] [Reference Citation Analysis]
397 Dong H, Liu G, Jiang B, Guo J, Tao G, Yiu W, Zhou J, Li G. Overexpression of the Survivin gene in SGC7901 cell resistance to cisplatin. Oncol Lett 2014;8:1953-6. [PMID: 25295077 DOI: 10.3892/ol.2014.2463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
398 Neuwelt AJ, Wu YJ, Knap N, Losin M, Neuwelt EA, Pagel MA, Warmann S, Fuchs J, Czauderna P, Wozniak M. Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia 2009;11:1003-11. [PMID: 19794959 DOI: 10.1593/neo.09688] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
399 Kozelka J. Molecular origin of the sequence-dependent kinetics of reactions between cisplatin derivatives and DNA. Inorganica Chimica Acta 2009;362:651-68. [DOI: 10.1016/j.ica.2008.04.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
400 Iida T, Kijima H, Urata Y, Goto S, Ihara Y, Oka M, Kohno S, Scanlon KJ, Kondo T. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther 2001;8:803-14. [PMID: 11687904 DOI: 10.1038/sj.cgt.7700371] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
401 Zwang TJ, Singh K, Johal MS, Selassie CR. Elucidation of the Molecular Interaction between Cisplatin and Flavonol(s) and their Effect on DNA Binding. J Med Chem 2013;56:1491-8. [DOI: 10.1021/jm3016798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
402 Hanigan MH, Gallagher BC, Townsend DM, Gabarra V. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 1999;20:553-9. [PMID: 10223181 DOI: 10.1093/carcin/20.4.553] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 5.0] [Reference Citation Analysis]
403 Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene. 2003;22:7512-7523. [PMID: 14576855 DOI: 10.1038/sj.onc.1206951] [Cited by in Crossref: 257] [Cited by in F6Publishing: 237] [Article Influence: 14.3] [Reference Citation Analysis]
404 Meyer TE, Liang HQ, Buckley AR, Buckley DJ, Gout PW, Green EH, Bode AM. Changes in glutathione redox cycling and oxidative stress response in the malignant progression of NB2 lymphoma cells. Int J Cancer 1998;77:55-63. [DOI: 10.1002/(sici)1097-0215(19980703)77:1<55::aid-ijc10>3.0.co;2-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
405 Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464-472. [PMID: 18648370 DOI: 10.1038/sj.bjc.6604485] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
406 Ciaccio P, Jaiswal A, Tew K. Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. Journal of Biological Chemistry 1994;269:15558-62. [DOI: 10.1016/s0021-9258(17)40716-2] [Cited by in Crossref: 28] [Article Influence: 1.0] [Reference Citation Analysis]
407 Ishida H, Kijima H, Ohta Y, Kashani-sabet M, Scanlon KJ. Mechanisms of Cisplatin Resistance and Its Reversal In Human Tumors. In: Kellen JA, editor. Alternative Mechanisms of Multidrug Resistance in Cancer. Boston: Birkhäuser; 1995. pp. 225-64. [DOI: 10.1007/978-1-4615-9852-7_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
408 Chu C, Lyu X, Wang Z, Jin H, Lu S, Xing D, Hu X. Cocktail polyprodrug nanoparticles concurrently release cisplatin and peroxynitrite-generating nitric oxide in cisplatin-resistant cancers. Chemical Engineering Journal 2020;402:126125. [DOI: 10.1016/j.cej.2020.126125] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
409 Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res. 2002;93:1047-1056. [PMID: 12359059 DOI: 10.1111/j.1349-7006.2002.tb02482.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
410 Li L, Shi W, Wang Z, Gong Q, Ma H. Sensitive Fluorescence Probe with Long Analytical Wavelengths for γ-Glutamyl Transpeptidase Detection in Human Serum and Living Cells. Anal Chem 2015;87:8353-9. [DOI: 10.1021/acs.analchem.5b01535] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
411 Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA, Gottesman MM. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 2003;88:1327-34. [PMID: 12698203 DOI: 10.1038/sj.bjc.6600861] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 4.1] [Reference Citation Analysis]
412 Yin P, Song G, Jiang Z. Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1. Cancer Chemother Pharmacol 2018;81:863-72. [PMID: 29536130 DOI: 10.1007/s00280-018-3536-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
413 Kinoshita C, Aoyama K, Nakaki T. Neuroprotection afforded by circadian regulation of intracellular glutathione levels: A key role for miRNAs. Free Radic Biol Med 2018;119:17-33. [PMID: 29198727 DOI: 10.1016/j.freeradbiomed.2017.11.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
414 Marraccini P, Iantomasi T, Rigacci S, Pacini S, Ruggiero M, Vincenzini MT, Ramponi G. Effect of phosphotyrosine phosphatase over-expression on glutathione metabolism in normal and oncogene-transformed cells. FEBS Letters 1994;344:157-60. [DOI: 10.1016/0014-5793(94)00377-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
415 Verma H, Singh Bahia M, Choudhary S, Kumar Singh P, Silakari O. Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it. Drug Metabolism Reviews 2019;51:196-223. [DOI: 10.1080/03602532.2019.1632886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
416 Park EY, Ki SH, Ko MS, Kim CW, Lee MH, Lee YS, Kim SG. Garlic oil and DDB, comprised in a pharmaceutical composition for the treatment of patients with viral hepatitis, prevents acute liver injuries potentiated by glutathione deficiency in rats. Chem Biol Interact. 2005;155:82-96. [PMID: 15950962 DOI: 10.1016/j.cbi.2005.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
417 El-Sahli S, Xie Y, Wang L, Liu S. Wnt Signaling in Cancer Metabolism and Immunity. Cancers (Basel) 2019;11:E904. [PMID: 31261718 DOI: 10.3390/cancers11070904] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
418 Piktel E, Prokop I, Wnorowska U, Król G, Cieśluk M, Niemirowicz K, Savage PB, Bucki R. Ceragenin CSA-13 as free molecules and attached to magnetic nanoparticle surfaces induce caspase-dependent apoptosis in human breast cancer cells via disruption of cell oxidative balance. Oncotarget 2018;9:21904-20. [PMID: 29774111 DOI: 10.18632/oncotarget.25105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
419 Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67:3364-3370. [PMID: 17409446 DOI: 10.1158/0008-5472.can-06-3717] [Cited by in Crossref: 157] [Cited by in F6Publishing: 96] [Article Influence: 11.2] [Reference Citation Analysis]
420 El-senduny FF, Badria FA, El-waseef AM, Chauhan SC, Halaweish F. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumor Biol 2016;37:685-98. [DOI: 10.1007/s13277-015-3773-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
421 Petruzzella E, Curci A, Margiotta N, Natile G, Hoeschele JD. Kiteplatin: Differential binding between GSH and GMP. Inorganica Chimica Acta 2016;452:130-6. [DOI: 10.1016/j.ica.2016.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
422 Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett 2016;381:96-103. [PMID: 27477897 DOI: 10.1016/j.canlet.2016.07.035] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 17.0] [Reference Citation Analysis]
423 Hirst J, Pathak HB, Hyter S, Pessetto ZY, Ly T, Graw S, Koestler DC, Krieg AJ, Roby KF, Godwin AK. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties. Cancer Res 2018;78:4370-85. [PMID: 29891506 DOI: 10.1158/0008-5472.CAN-17-3993] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
424 Pan H, Kim E, Rankin GO, Rojanasakul Y, Tu Y, Chen YC. Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells. Int J Mol Sci 2018;19:E117. [PMID: 29301278 DOI: 10.3390/ijms19010117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
425 Bose RN, Maurmann L, Mishur RJ, Yasui L, Gupta S, Grayburn WS, Hofstetter H, Salley T. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc Natl Acad Sci U S A 2008;105:18314-9. [PMID: 19020081 DOI: 10.1073/pnas.0803094105] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
426 Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R, Terakawa N. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. European Journal of Cancer 2000;36:1863-8. [DOI: 10.1016/s0959-8049(00)00183-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
427 Winter S, Strik H, Rieger J, Beck J, Meyermann R, Weller M. Glutathione S-transferase and drug sensitivity in malignant glioma. Journal of the Neurological Sciences 2000;179:115-21. [DOI: 10.1016/s0022-510x(00)00392-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
428 Marker SC, King AP, Swanda RV, Vaughn B, Boros E, Qian SB, Wilson JJ. Exploring ovarian cancer cell resistance to rhenium anticancer complexes. Angew Chem Weinheim Bergstr Ger 2020;132:13493-502. [PMID: 34366495 DOI: 10.1002/ange.202004883] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
429 Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Mol Cancer Ther 2016;15:1557-67. [PMID: 27196780 DOI: 10.1158/1535-7163.MCT-15-0926] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
430 Jia Y, Zhang C, Zhou L, Xu H, Shi Y, Tong Z. Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathione. Onco Targets Ther. 2015;8:2319-2327. [PMID: 26356142 DOI: 10.2147/OTT.S88661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
431 Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R, Podo F, Canevari S, Iorio E, Mezzanzanica D. Choline Metabolism Alteration: A Focus on Ovarian Cancer. Front Oncol 2016;6:153. [PMID: 27446799 DOI: 10.3389/fonc.2016.00153] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
432 Dominici S, Valentini M, Maellaro E, Del Bello B, Paolicchi A, Lorenzini E, Tongiani R, Comporti M, Pompella A. Redox modulation of cell surface protein thiols in U937 lymphoma cells: the role of gamma-glutamyl transpeptidase-dependent H2O2 production and S-thiolation. Free Radic Biol Med. 1999;27:623-635. [PMID: 10490284 DOI: 10.1016/s0891-5849(99)00111-2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
433 Zadeh Fakhar HB, Zali H, Rezaie-Tavirani M, Darkhaneh RF, Babaabasi B. Proteome profiling of low grade serous ovarian cancer. J Ovarian Res 2019;12:64. [PMID: 31315664 DOI: 10.1186/s13048-019-0535-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
434 Cruz A, Mota P, Ramos C, Pires RF, Mendes C, Silva JP, Nunes SC, Bonifácio VDB, Serpa J. Polyurea Dendrimer Folate-Targeted Nanodelivery of l-Buthionine sulfoximine as a Tool to Tackle Ovarian Cancer Chemoresistance. Antioxidants (Basel) 2020;9:E133. [PMID: 32028640 DOI: 10.3390/antiox9020133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
435 Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL; Australian Ovarian Cancer Study (AOCS). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 2018;9:3970. [PMID: 30266954 DOI: 10.1038/s41467-018-05564-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 27.7] [Reference Citation Analysis]
436 Kalayda GV, Jansen BAJ, Molenaar C, Wielaard P, Tanke HJ, Reedijk J. Dinuclear platinum complexes with N,N′-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance. J Biol Inorg Chem 2004;9:414-22. [DOI: 10.1007/s00775-004-0540-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
437 Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. Lung Cancer 2013;82:222-30. [PMID: 24041618 DOI: 10.1016/j.lungcan.2013.08.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
438 Sohal RS, Forster MJ. Caloric restriction and the aging process: a critique. Free Radic Biol Med 2014;73:366-82. [PMID: 24941891 DOI: 10.1016/j.freeradbiomed.2014.05.015] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 14.1] [Reference Citation Analysis]
439 Thomas F, Chatelut E. Les dérivés du platine. Oncologie 2007;9:741-5. [DOI: 10.1007/s10269-007-0700-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
440 Daubeuf S, Leroy P, Paolicchi A, Pompella A, Wellman M, Galteau MM, Visvikis A. Enhanced resistance of HeLa cells to cisplatin by overexpression of gamma-glutamyltransferase. Biochem Pharmacol 2002;64:207-16. [PMID: 12123741 DOI: 10.1016/s0006-2952(02)01118-8] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
441 Perego P, Vande Weghe J, Ow DW, Howell SB. Role of Determinants of Cadmium Sensitivity in the Tolerance of Schizosaccharomyces pombe to Cisplatin. Mol Pharmacol 1997;51:12-8. [DOI: 10.1124/mol.51.1.12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
442 Huang ZA, Yang H, Chen C, Zeng Z, Lu SC. Inducers of gamma-glutamylcysteine synthetase and their effects on glutathione synthetase expression. Biochim Biophys Acta 2000;1493:48-55. [PMID: 10978506 DOI: 10.1016/s0167-4781(00)00156-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
443 Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT. Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene 2017;36:4235-42. [PMID: 27869167 DOI: 10.1038/onc.2016.394] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
444 Roudier E, Perrin A. Considering the role of pyruvate in tumor cells during hypoxia. Biochim Biophys Acta 2009;1796:55-62. [PMID: 19268693 DOI: 10.1016/j.bbcan.2009.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
445 Moyer AM, Sun Z, Batzler AJ, Li L, Schaid DJ, Yang P, Weinshilboum RM. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 2010;19:811-21. [PMID: 20200426 DOI: 10.1158/1055-9965.EPI-09-0871] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
446 Yu JJ, Bicher A, Ma YK, Bostick-bruton F, Reed E. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues. Cancer Letters 2000;151:127-32. [DOI: 10.1016/s0304-3835(99)00390-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
447 Segelov E, Mann G, deFazio A, Harnett PR. Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. Mutation Research/DNA Repair 1998;407:243-52. [DOI: 10.1016/s0921-8777(98)00006-8] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
448 Franke CE, Czapar AE, Patel RB, Steinmetz NF. Tobacco Mosaic Virus-Delivered Cisplatin Restores Efficacy in Platinum-Resistant Ovarian Cancer Cells. Mol Pharm 2018;15:2922-31. [PMID: 28926265 DOI: 10.1021/acs.molpharmaceut.7b00466] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
449 Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 1996;73:610-4. [PMID: 8605094 DOI: 10.1038/bjc.1996.105] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
450 Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011;17:6356-66. [PMID: 21849418 DOI: 10.1158/1078-0432.CCR-11-0735] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
451 Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. Jpn J Cancer Res 1995;86:88-94. [PMID: 7737915 DOI: 10.1111/j.1349-7006.1995.tb02992.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
452 Chen G, Hutter KJ, Zeller WJ. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 1995;11:273-81. [PMID: 8608408 DOI: 10.1007/BF00757625] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
453 Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulias V, Souglakos J. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. Br J Cancer 2014;111:1757-64. [PMID: 25233397 DOI: 10.1038/bjc.2014.492] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
454 Menga A, Palmieri EM, Cianciulli A, Infantino V, Mazzone M, Scilimati A, Palmieri F, Castegna A, Iacobazzi V. SLC25A26 overexpression impairs cell function via mtDNA hypermethylation and rewiring of methyl metabolism. FEBS J 2017;284:967-84. [PMID: 28118529 DOI: 10.1111/febs.14028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
455 Cooley M, Fang P, Fang F, Nephew KP, Chien J. Molecular determinants of chemotherapy resistance in ovarian cancer. Pharmacogenomics 2015;16:1763-7. [PMID: 26554863 DOI: 10.2217/pgs.15.130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
456 Hanigan MH. gamma-Glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis. Chem Biol Interact 1998;111-112:333-42. [PMID: 9679564 DOI: 10.1016/s0009-2797(97)00170-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
457 Billings PC, Engelsberg BN, Hughes EN. Proteins Binding to Cisplatin-Damaged DNA in Human Cell Lines. Cancer Investigation 2009;12:597-604. [DOI: 10.3109/07357909409023044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
458 Tanaka T, Uchiumi T, Nomoto M, Kohno K, Kondo T, Nishio K, Saijo N, Kuwano M. Cellular balance of glutathione levels through the expression of γ-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison. Biochimica et Biophysica Acta (BBA) - General Subjects 1999;1427:367-77. [DOI: 10.1016/s0304-4165(99)00016-1] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
459 Vermathen M, Paul LE, Diserens G, Vermathen P, Furrer J. 1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug. PLoS One 2015;10:e0128478. [PMID: 26024484 DOI: 10.1371/journal.pone.0128478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
460 Miyata Y, Ishizawa T, Kamiya M, Yamashita S, Hasegawa K, Ushiku A, Shibahara J, Fukayama M, Urano Y, Kokudo N. Intraoperative imaging of hepatic cancers using γ-glutamyltranspeptidase-specific fluorophore enabling real-time identification and estimation of recurrence. Sci Rep 2017;7:3542. [PMID: 28615696 DOI: 10.1038/s41598-017-03760-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
461 Caverzán MD, Beaugé L, Chesta CA, Palacios RE, Ibarra LE. Photodynamic therapy of Glioblastoma cells using doped conjugated polymer nanoparticles: An in vitro comparative study based on redox status. J Photochem Photobiol B 2020;212:112045. [PMID: 33022469 DOI: 10.1016/j.jphotobiol.2020.112045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
462 Hong JH, Lee E, Hong J, Shin YJ, Ahn H. Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 2002;90:113-7. [PMID: 12081782 DOI: 10.1046/j.1464-410x.2002.02799.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
463 Surnar B, Kolishetti N, Basu U, Ahmad A, Goka E, Marples B, Kolb D, Lippman ME, Dhar S. Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity. Biochemistry 2018;57:6500-13. [DOI: 10.1021/acs.biochem.8b00712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
464 Pan Z, Sampath D, Jackson G, Werrbach-perez K, Perez-polo R. Nerve Growth Factor and Oxidative Stress in the Nervous System. In: Filogamo G, Vernadakis A, Gremo F, Privat AM, Timiras PS, editors. Brain Plasticity. Boston: Springer US; 1997. pp. 173-93. [DOI: 10.1007/978-1-4757-9551-6_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
465 Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T, Bannai S. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer 2003;88:951-6. [PMID: 12644836 DOI: 10.1038/sj.bjc.6600786] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 6.2] [Reference Citation Analysis]
466 Soykut B, Erdem O, Akay C, Pişkin B. Investigation of the oxidative stress condition for occupational exposure to methyl methacrylate. Toxicol Ind Health 2017;33:61-6. [DOI: 10.1177/0748233716659840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
467 Wild AC, Mulcahy RT. Regulation of γ -glutamylcysteine synthetase subunit gene expression: Insights into transcriptional control of antioxidant defenses. Free Radical Research 2009;32:281-301. [DOI: 10.1080/10715760000300291] [Cited by in Crossref: 144] [Cited by in F6Publishing: 146] [Article Influence: 12.0] [Reference Citation Analysis]
468 Crow J, Atay S, Banskota S, Artale B, Schmitt S, Godwin AK. Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget 2017;8:11917-36. [PMID: 28060758 DOI: 10.18632/oncotarget.14440] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
469 Mellish KJ, Barnard CFJ, Kelland LR, Harrap KR. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novelTrans platinum complex, JM335 [Trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]. Int J Cancer 1994;59:65-70. [DOI: 10.1002/ijc.2910590114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
470 Moayeri M, Wiggins JF, Lindeman RE, Leppla SH. Cisplatin inhibition of anthrax lethal toxin. Antimicrob Agents Chemother 2006;50:2658-65. [PMID: 16870755 DOI: 10.1128/AAC.01412-05] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
471 Garrido N, Pérez-Martos A, Faro M, Lou-Bonafonte JM, Fernández-Silva P, López-Pérez MJ, Montoya J, Enríquez JA. Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. Biochem J 2008;414:93-102. [PMID: 18426391 DOI: 10.1042/BJ20071615] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
472 Bellamy WT. The Role of Glutathione S-Transferases in Drug Resistance. In: Kellen JA, editor. Alternative Mechanisms of Multidrug Resistance in Cancer. Boston: Birkhäuser; 1995. pp. 31-65. [DOI: 10.1007/978-1-4615-9852-7_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
473 Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619-634. [PMID: 27492215 DOI: 10.1038/nrc.2016.71] [Cited by in Crossref: 656] [Cited by in F6Publishing: 612] [Article Influence: 131.2] [Reference Citation Analysis]
474 Greenwood HE, McCormick PN, Gendron T, Glaser M, Pereira R, Maddocks ODK, Sander K, Zhang T, Koglin N, Lythgoe MF, Årstad E, Hochhauser D, Witney TH. Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography. Clin Cancer Res 2019;25:2471-82. [PMID: 30651275 DOI: 10.1158/1078-0432.CCR-18-3423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
475 Štarha P, Trávníček Z, Drahoš B, Herchel R, Dvořák Z. Cell-based studies of the first-in-class half-sandwich Ir(III) complex containing histone deacetylase inhibitor 4-phenylbutyrate: Half-sandwich Ir(III) complex containing 4-phenylbutyrate. Appl Organometal Chem 2018;32:e4246. [DOI: 10.1002/aoc.4246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
476 Le'Negrate G, Ricci V, Hofman V, Mograbi B, Hofman P, Rossi B. Epithelial intestinal cell apoptosis induced by Helicobacter pylori depends on expression of the cag pathogenicity island phenotype. Infect Immun. 2001;69:5001-5009. [PMID: 16303117 DOI: 10.1016/j.bcp.2005.10.005] [Cited by in Crossref: 167] [Cited by in F6Publishing: 168] [Article Influence: 10.4] [Reference Citation Analysis]
477 Yabana T, Sato K, Shiga Y, Himori N, Omodaka K, Nakazawa T. The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma. PLoS One 2019;14:e0227078. [PMID: 31887133 DOI: 10.1371/journal.pone.0227078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
478 Kwon Y, Cukierman E, Godwin AK. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One 2011;6:e18872. [PMID: 21526198 DOI: 10.1371/journal.pone.0018872] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
479 Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer. 2002;95:1802-1815. [PMID: 12365030 DOI: 10.1002/cncr.10870] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
480 Qi D, Kaur Gill N, Santiskulvong C, Sifuentes J, Dorigo O, Rao J, Taylor-Harding B, Ruprecht Wiedemeyer W, Rowat AC. Screening cell mechanotype by parallel microfiltration. Sci Rep 2015;5:17595. [PMID: 26626154 DOI: 10.1038/srep17595] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
481 Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 2005;24:3574-3582. [PMID: 15806173 DOI: 10.1038/sj.onc.1208463] [Cited by in Crossref: 128] [Cited by in F6Publishing: 111] [Article Influence: 8.0] [Reference Citation Analysis]
482 Fujii T, Hamaoka R, Fujii J, Taniguchi N. Redox capacity of cells affects inactivation of glutathione reductase by nitrosative stress. Arch Biochem Biophys 2000;378:123-30. [PMID: 10871052 DOI: 10.1006/abbi.2000.1825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
483 Bai L, Gao C, Liu Q, Yu C, Zhang Z, Cai L, Yang B, Qian Y, Yang J, Liao X. Research progress in modern structure of platinum complexes. Eur J Med Chem 2017;140:349-82. [PMID: 28985575 DOI: 10.1016/j.ejmech.2017.09.034] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
484 Nishimoto M, Le Eberhart B, Sanborn HR, Krone C, Varanasi U, Stein JE. Effects of a complex mixture of chemical contaminants on hepatic glutathione, L-cysteine and γ-glutamylcysteine synthetase in english sole ( Pleuronectes vetulus ). Environ Toxicol Chem 1995;14:461-9. [DOI: 10.1002/etc.5620140316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
485 Sakurai H, Okamoto M, Hasegawa M, Satoh T, Oikawa M, Kamiya T, Arakawa K, Nakano T. Direct visualization and quantification of the anticancer agent, cis-diamminedichloro-platinum(II), in human lung cancer cells using in-air microparticle-induced X-ray emission analysis. Cancer Sci 2008;99:901-4. [PMID: 18294282 DOI: 10.1111/j.1349-7006.2008.00755.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
486 Ling X, Chen X, Riddell IA, Tao W, Wang J, Hollett G, Lippard SJ, Farokhzad OC, Shi J, Wu J. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. Nano Lett 2018;18:4618-25. [PMID: 29902013 DOI: 10.1021/acs.nanolett.8b01924] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 32.3] [Reference Citation Analysis]
487 Petrović D, Stojimirović B, Petrović B, Bugarčić ZM, Bugarčić ŽD. Studies of interactions between platinum(II) complexes and some biologically relevant molecules. Bioorganic & Medicinal Chemistry 2007;15:4203-11. [DOI: 10.1016/j.bmc.2007.03.059] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
488 Noda T, Iwakiri R, Fujimoto K, Aw TY. Induction of mild intracellular redox imbalance inhibits proliferation of CaCo-2 cells. FASEB J. 2001;15:2131-2139. [PMID: 11641239 DOI: 10.1096/fj.01-0131com] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 3.7] [Reference Citation Analysis]
489 Iba T, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Simada M, Uegaki K, Naniwa J, Terakawa N. Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Science 2004;95:418-23. [DOI: 10.1111/j.1349-7006.2004.tb03225.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
490 Bugarčić ŽD, Heinemann FW, Eldik RV. Substitution reactions of [Pt(terpy)X] 2+ with some biologically relevant ligands. Synthesis and crystal structure of [Pt(terpy)(cyst-S)](ClO 4 ) 2 ·0.5H 2 O and [Pt(terpy)(guo-N 7 )](ClO 4 ) 2 ·0.5guo·1.5H 2 O. Dalton Trans 2004. [DOI: 10.1039/b311056g] [Cited by in Crossref: 66] [Cited by in F6Publishing: 6] [Article Influence: 3.9] [Reference Citation Analysis]
491 Kikuchi Y, Hirata J, Yamamoto K, Ishii K, Kita T, Kudoh K, Tode T, Nagata I, Taniguchi K, Kuwano M. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res. 1997;88:213-217. [PMID: 9119751 DOI: 10.1111/j.1349-7006.1997.tb00368.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
492 Das GC, Bacsi A, Shrivastav M, Hazra TK, Boldogh I. Enhanced γ-glutamylcysteine synthetase activity decreases drug-induced oxidative stress levels and cytotoxicity: γ-GLUTAMYLCYSTEINE SYNTHETASE DECREASES DRUG-INDUCED ROS LEVELS. Mol Carcinog 2006;45:635-47. [DOI: 10.1002/mc.20184] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
493 Li Q, Gardner K, Zhang L, Tsang B, Bostick-bruton F, Reed E. Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells. Journal of Biological Chemistry 1998;273:23419-25. [DOI: 10.1074/jbc.273.36.23419] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 3.5] [Reference Citation Analysis]
494 Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol 2008;75:627-38. [PMID: 18178171 DOI: 10.1016/j.bcp.2007.09.029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
495 Pendyala L, Creaven PJ, Perez R, Zdanowicz JR, Raghavan D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol 1995;36:271-8. [DOI: 10.1007/bf00689042] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
496 Shoeib T, Sharp BL. Monomeric cisplatin complexes with glutathione: Coordination modes and binding affinities. Inorganica Chimica Acta 2013;405:258-64. [DOI: 10.1016/j.ica.2013.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
497 Iwanaga M, Mori K, Iida T, Urata Y, Matsuo T, Yasunaga A, Shibata S, Kondo T. Nuclear factor kappa B dependent induction of gamma glutamylcysteine synthetase by ionizing radiation in T98G human glioblastoma cells. Free Radic Biol Med 1998;24:1256-68. [PMID: 9626582 DOI: 10.1016/s0891-5849(97)00443-7] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
498 Saifullina DV, Shakhmaeva II, Abdullin TI. Assessment of metabolic activity of human cells in solution and in polymer matrix with the use of metabolite-sensitive sensors. Mater Sci Eng C Mater Biol Appl 2012;32:1843-8. [PMID: 34062665 DOI: 10.1016/j.msec.2012.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
499 Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treatment Reviews 2003;29:501-13. [DOI: 10.1016/s0305-7372(03)00133-6] [Cited by in Crossref: 165] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
500 Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, Wang J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol. 2010;79:1134-1140. [PMID: 20005210 DOI: 10.1016/j.bcp.2009.12.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
501 Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N, Yokoyama T. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Letters 2009;278:88-96. [DOI: 10.1016/j.canlet.2008.12.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
502 Zheng ZG, Xu H, Suo SS, Xu XL, Ni MW, Gu LH, Chen W, Wang LY, Zhao Y, Tian B, Hua YJ. The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer. Sci Rep 2016;6:26093. [PMID: 27193186 DOI: 10.1038/srep26093] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 15.8] [Reference Citation Analysis]
503 Roth E, Oehler R, Manhart N, Exner R, Wessner B, Strasser E, Spittler A. Regulative potential of glutamine--relation to glutathione metabolism. Nutrition 2002;18:217-21. [PMID: 11882392 DOI: 10.1016/s0899-9007(01)00797-3] [Cited by in Crossref: 141] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
504 Kumari S, Pal RK, Gupta R, Goel M. High Resolution X-ray Diffraction Dataset for Bacillus licheniformis Gamma Glutamyl Transpeptidase-acivicin complex: SUMO-Tag Renders High Expression and Solubility. Protein J 2017;36:7-16. [PMID: 28120227 DOI: 10.1007/s10930-017-9693-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
505 Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resist Updat 2016;24:55-69. [PMID: 26830315 DOI: 10.1016/j.drup.2015.11.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
506 Rigacci S, Iantomasi T, Marraccini P, Berti A, Vincenzini MT, Ramponi G. Evidence for glutathione involvement in platelet-derived growth-factor-mediated signal transduction. Biochem J 1997;324 ( Pt 3):791-6. [PMID: 9210402 DOI: 10.1042/bj3240791] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
507 Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Biochemical Pharmacology 2000;60:1305-13. [DOI: 10.1016/s0006-2952(00)00441-x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
508 Ise T, Izumi H, Nagatani G, Takano H, Wada M, Kuwano M, Kohno K. Structural characterization of the human interleukin-13 receptor alpha1 gene promoter. Biochem Biophys Res Commun 1999;265:387-94. [PMID: 10558877 DOI: 10.1006/bbrc.1999.1701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
509 Samper KG, Marker SC, Bayón P, Macmillan SN, Keresztes I, Palacios Ò, Wilson JJ. Reprint of “Anticancer activity of hydroxy- and sulfonamide-azobenzene platinum(II) complexes in cisplatin-resistant ovarian cancer cells”. Journal of Inorganic Biochemistry 2017;177:335-43. [DOI: 10.1016/j.jinorgbio.2017.07.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
510 Shen DW, Goldenberg S, Pastan I, Gottesman MM. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 2000;183:108-16. [PMID: 10699972 DOI: 10.1002/(SICI)1097-4652(200004)183:1<108::AID-JCP13>3.0.CO;2-4] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
511 Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999;31:549-58. [PMID: 10630679 DOI: 10.1080/10715769900301121] [Cited by in Crossref: 146] [Cited by in F6Publishing: 135] [Article Influence: 7.0] [Reference Citation Analysis]
512 Dabrowiak JC, Goodisman J, Souid AK. Kinetic study of the reaction of cisplatin with thiols. Drug Metab Dispos 2002;30:1378-84. [PMID: 12433807 DOI: 10.1124/dmd.30.12.1378] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 3.4] [Reference Citation Analysis]
513 Muggia FM, Los G. Platinum resistance: laboratory findings and clinical implications. Stem Cells 1993;11:182-93. [PMID: 8318904 DOI: 10.1002/stem.5530110304] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
514 Luo M, Sun W, Wu C, Zhang L, Liu D, Li W, Mei Q, Hu G. High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma. Oncotarget 2017;8:67651-62. [PMID: 28978060 DOI: 10.18632/oncotarget.18798] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
515 Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502-516. [PMID: 12835670 DOI: 10.1038/nrc1123] [Cited by in Crossref: 744] [Cited by in F6Publishing: 701] [Article Influence: 41.3] [Reference Citation Analysis]
516 Galloway DC, Blake DG, Shepherd AG, McLellan LI. Regulation of human gamma-glutamylcysteine synthetase: co-ordinate induction of the catalytic and regulatory subunits in HepG2 cells. Biochem J 1997;328 ( Pt 1):99-104. [PMID: 9359839 DOI: 10.1042/bj3280099] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 3.8] [Reference Citation Analysis]
517 Cheteh EH, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L, Bykov VJ, Östman A, Wiman KG. Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death Dis 2017;8:e2848. [PMID: 28569790 DOI: 10.1038/cddis.2017.225] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
518 Handel ML, Girgis L. Transcription factors. Best Practice & Research Clinical Rheumatology 2001;15:657-75. [DOI: 10.1053/berh.2001.0186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
519 Keillor JW, Castonguay R, Lherbet C. Gamma-glutamyl transpeptidase substrate specificity and catalytic mechanism. Methods Enzymol 2005;401:449-67. [PMID: 16399402 DOI: 10.1016/S0076-6879(05)01027-X] [Cited by in Crossref: 62] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
520 Kumar S, Oien DB, Khurana A, Cliby W, Hartmann L, Chien J, Shridhar V. Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. Front Oncol 2019;9:986. [PMID: 31632917 DOI: 10.3389/fonc.2019.00986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
521 Foyer CH, Noctor G. The Molecular Biology and Metabolism of Glutathione. In: Grill D, Tausz M, De Kok LJ, editors. Significance of Glutathione to Plant Adaptation to the Environment. Dordrecht: Springer Netherlands; 2001. pp. 27-56. [DOI: 10.1007/0-306-47644-4_3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
522 McDonald ME, Salinas EA, Devor EJ, Newtson AM, Thiel KW, Goodheart MJ, Bender DP, Smith BJ, Leslie KK, Gonzalez-Bosquet J. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer. Int J Mol Sci 2019;20:E1175. [PMID: 30866519 DOI: 10.3390/ijms20051175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
523 Cocetta V, Ragazzi E, Montopoli M. Links between cancer metabolism and cisplatin resistance. Int Rev Cell Mol Biol 2020;354:107-64. [PMID: 32475471 DOI: 10.1016/bs.ircmb.2020.01.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
524 Helm CW, States JC. Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. J Ovarian Res 2009;2:2. [PMID: 19144189 DOI: 10.1186/1757-2215-2-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
525 Bai H, Li H, Li W, Gui T, Yang J, Cao D, Shen K. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget 2015;6:25520-32. [PMID: 26267321 DOI: 10.18632/oncotarget.4550] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
526 Thioudellet C, Oster T, Wellman M, Siest G. Molecular and functional characterization of recombinant human gamma-glutamyltransferase. Coupling of its activity to glutathione levels in V79 cells. Eur J Biochem 1994;222:1009-16. [PMID: 7913033 DOI: 10.1111/j.1432-1033.1994.tb18952.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
527 Taniguchi N, Ikeda Y. gamma-Glutamyl transpeptidase: catalytic mechanism and gene expression. Adv Enzymol Relat Areas Mol Biol 1998;72:239-78. [PMID: 9559055 DOI: 10.1002/9780470123188.ch7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
528 Lusk H, Burdette JE, Sanchez LM. Models for measuring metabolic chemical changes in the metastasis of high grade serous ovarian cancer: fallopian tube, ovary, and omentum. Mol Omics 2021. [PMID: 34338690 DOI: 10.1039/d1mo00074h] [Reference Citation Analysis]
529 Romo AIB, Carepo MP, Levín P, Nascimento OR, Díaz DE, Rodríguez-López J, León IE, Bezerra LF, Lemus L, Diógenes ICN. Synergy of DNA intercalation and catalytic activity of a copper complex towards improved polymerase inhibition and cancer cell cytotoxicity. Dalton Trans 2021;50:11931-40. [PMID: 34374389 DOI: 10.1039/d1dt01358k] [Reference Citation Analysis]
530 Kuroda H, Takeno M, Murakami S, Miyazawa N, Kaneko T, Ishigatsubo Y. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 2010;67:31-6. [PMID: 19375813 DOI: 10.1016/j.lungcan.2009.03.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
531 Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC. Cancer Biol Ther 2014;15:1367-77. [PMID: 25025901 DOI: 10.4161/cbt.29841] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
532 Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97:26-34. [PMID: 15790433 DOI: 10.1016/j.ygyno.2004.11.051] [Cited by in Crossref: 162] [Cited by in F6Publishing: 144] [Article Influence: 10.1] [Reference Citation Analysis]
533 Oien DB, Garay T, Eckstein S, Chien J. Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. Front Pharmacol 2017;8:970. [PMID: 29375377 DOI: 10.3389/fphar.2017.00970] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
534 Li XM, Metzger G, Filipski E, Boughattas N, Lemaigre G, Hecquet B, Filipski J, Levi F. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol Appl Pharmacol 1997;143:281-90. [PMID: 9144445 DOI: 10.1006/taap.1996.8088] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
535 Parekh H, Simpkins H. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemother Pharmacol 1996;37:457-62. [DOI: 10.1007/s002800050412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
536 Siddik ZH. Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 2002;112:263-84. [PMID: 12481720 DOI: 10.1007/978-1-4615-1173-1_13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
537 Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol 2018;31:15-25. [DOI: 10.1007/s40620-017-0392-z] [Cited by in Crossref: 187] [Cited by in F6Publishing: 179] [Article Influence: 46.8] [Reference Citation Analysis]
538 Chistyakov VA, Prazdnova EV, Mazanko MS, Churilov MN, Chmyhalo VK. Increase in Bacterial Resistance to Antibiotics after Cancer Therapy with Platinum-Based Drugs. Mol Biol 2018;52:232-6. [DOI: 10.1134/s0026893317050077] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
539 Abildgaard C, Do Canto LM, Steffensen KD, Rogatto SR. Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer. Front Oncol 2019;9:1549. [PMID: 32039022 DOI: 10.3389/fonc.2019.01549] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 22.0] [Reference Citation Analysis]
540 Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 2008;38:833-62. [DOI: 10.1080/00498250701883514] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
541 Yanagisawa T, Urade M, Takahashi Y, Yamamoto Y, Furuyama J. Levels of superoxide dismutases, glutathione, and poly(ADP-ribose) polymerase in radioresistant human KB carcinoma cell line. Jpn J Cancer Res 1997;88:1070-7. [PMID: 9439682 DOI: 10.1111/j.1349-7006.1997.tb00331.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
542 Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653-8. [PMID: 18377417 DOI: 10.1111/j.1349-7006.2008.00747.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 12.2] [Reference Citation Analysis]
543 Strohkamp S, Gemoll T, Humborg S, Hartwig S, Lehr S, Freitag-Wolf S, Becker S, Franzén B, Pries R, Wollenberg B, Roblick UJ, Bruch HP, Keck T, Auer G, Habermann JK. Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer. Cell Mol Life Sci 2018;75:323-34. [PMID: 28849249 DOI: 10.1007/s00018-017-2631-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
544 Tomonari A, Nishio K, Kurokawa H, Fukumoto H, Fukuoka K, Iwamoto Y, Usuda J, Suzuki T, Itakura M, Saijo N. Proximal 5′-Flanking Sequence of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene Is Involved in Cisplatin-Induced Transcriptional Up-regulation in a Lung Cancer Cell Line SBC-3. Biochemical and Biophysical Research Communications 1997;236:616-21. [DOI: 10.1006/bbrc.1997.7020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
545 Thiabaud G, Arambula JF, Siddik ZH, Sessler JL. Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate. Chemistry 2014;20:8942-7. [PMID: 24961491 DOI: 10.1002/chem.201403094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
546 Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen D, Feun LG, Kuo MT, Savaraj N. Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. Cell Dev Biol 2017;6:183. [PMID: 28819582 DOI: 10.4172/2168-9296.1000183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
547 Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 2011;104:1278-87. [PMID: 21487429 DOI: 10.1038/bjc.2011.84] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
548 Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002;9:62-70. [PMID: 11916245 DOI: 10.1038/sj.cgt.7700409] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
549 Prezioso JA, Hughey RP, Wang N, Damodaran KM, Bloomer WD. γ-glutamyltranspeptidase expression regulates the growth-inhibitory activity of the anti-tumor prodrug γ-L-glutaminyl-4-hydroxy-3-iodobenzene. Int J Cancer 1994;56:874-9. [DOI: 10.1002/ijc.2910560620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
550 Noda T, Iwakiri R, Fujimoto K, Rhoads CA, Aw TY. Exogenous cysteine and cystine promote cell proliferation in CaCo-2 cells. Cell Prolif 2002;35:117-29. [PMID: 11952646 DOI: 10.1046/j.1365-2184.2002.00229.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
551 Sun X, Wang S, Gai J, Guan J, Li J, Li Y, Zhao J, Zhao C, Fu L, Li Q. SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway. Front Oncol 2019;9:754. [PMID: 31456942 DOI: 10.3389/fonc.2019.00754] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
552 Jain N, Lam Y, Pym J, Campling BG. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 1996;77:1797-808. [DOI: 10.1002/(sici)1097-0142(19960501)77:9<1797::aid-cncr7>3.0.co;2-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
553 Wise DE, Gamble AJ, Arkawazi SW, Walton PH, Galan MC, O'hagan MP, Hogg KG, Marrison JL, O'toole PJ, Sparkes HA, Lynam JM, Pringle PG. Cytotoxic ( cis , cis -1,3,5-triaminocyclohexane)ruthenium( ii )-diphosphine complexes; evidence for covalent binding and intercalation with DNA. Dalton Trans 2020;49:15219-30. [DOI: 10.1039/d0dt02612c] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
554 Borud O, Mortensen B, Mikkelsen IM, Leroy P, Wellman M, Huseby N. Regulation of γ-glutamyltransferase in cisplatin-resistant and -sensitive colon carcinoma cells after acute cisplatin and oxidative stress exposures. Int J Cancer 2000;88:464-8. [DOI: 10.1002/1097-0215(20001101)88:3<464::aid-ijc20>3.0.co;2-f] [Cited by in Crossref: 21] [Article Influence: 1.0] [Reference Citation Analysis]
555 Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 1997;16:3057-65. [PMID: 9214623 DOI: 10.1093/emboj/16.11.3057] [Cited by in Crossref: 139] [Cited by in F6Publishing: 126] [Article Influence: 5.8] [Reference Citation Analysis]
556 Hamilton TC, Johnson SW, Godwin AK, Bookman MA, O’dwyer PJ, Hamaguchi K, Jackson K, Ozols RF. Drug resistance in ovarian cancer and potential for its reversal. In: Sharp F, Mason P, Blackett T, Berek J, editors. Ovarian Cancer 3. Boston: Springer US; 1994. pp. 203-13. [DOI: 10.1007/978-1-4757-0136-4_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
557 Hanigan MH, Frierson HF Jr, Abeler VM, Kaern J, Taylor PT Jr. Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin. Br J Cancer 1999;81:75-9. [PMID: 10487615 DOI: 10.1038/sj.bjc.6690653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
558 Muhammad N, Lee HM, Kim J. Oncology Therapeutics Targeting the Metabolism of Amino Acids. Cells 2020;9:E1904. [PMID: 32824193 DOI: 10.3390/cells9081904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
559 Mori K, Tani M, Kamata K, Kawamura H, Urata Y, Goto S, Kuwano M, Shibata S, Kondo T. Mitogen-activated protein kinase, ERK1/2, is essential for the induction of vascular endothelial growth factor by ionizing radiation mediated by activator protein-1 in human glioblastoma cells. Free Radic Res 2000;33:157-66. [PMID: 10885623 DOI: 10.1080/10715760000300711] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
560 Skovsgaard T, Nielsen D, Maare C, Wassermann K. Cellular Resistance to Cancer Chemotherapy. Elsevier; 1994. pp. 77-157. [DOI: 10.1016/s0074-7696(08)62253-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
561 Williams K, Cullati S, Sand A, Biterova EI, Barycki JJ. Crystal structure of acivicin-inhibited gamma-glutamyltranspeptidase reveals critical roles for its C-terminus in autoprocessing and catalysis. Biochemistry. 2009;48:2459-2467. [PMID: 19256527 DOI: 10.1021/bi8014955] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
562 Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis 2015;6:e1794. [PMID: 26086967 DOI: 10.1038/cddis.2015.143] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 15.2] [Reference Citation Analysis]
563 Kojima S, Matsuki O, Nomura T, Yamaoka K, Takahashi M, Niki E. Elevation of antioxidant potency in the brain of mice by low-dose gamma-ray irradiation and its effect on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced brain damage. Free Radic Biol Med 1999;26:388-95. [PMID: 9895231 DOI: 10.1016/s0891-5849(98)00200-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
564 London RE, Gabel SA. Development and evaluation of a boronate inhibitor of gamma-glutamyl transpeptidase. Arch Biochem Biophys 2001;385:250-8. [PMID: 11368005 DOI: 10.1006/abbi.2000.2169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
565 Badea MA, Prodana M, Dinischiotu A, Crihana C, Ionita D, Balas M. Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics 2018;10:E228. [PMID: 30428555 DOI: 10.3390/pharmaceutics10040228] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
566 Kondo T, Yoshida K, Urata Y, Goto S, Gasa S, Taniguchi N. gamma-Glutamylcysteine synthetase and active transport of glutathione S-conjugate are responsive to heat shock in K562 erythroid cells. Journal of Biological Chemistry 1993;268:20366-72. [DOI: 10.1016/s0021-9258(20)80737-6] [Cited by in Crossref: 52] [Article Influence: 1.9] [Reference Citation Analysis]
567 Buhrman JS, Cook LC, Rayahin JE, Federle MJ, Gemeinhart RA. Proteolytically activated anti-bacterial hydrogel microspheres. J Control Release 2013;171:288-95. [PMID: 23816641 DOI: 10.1016/j.jconrel.2013.06.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
568 Hyter S, Hirst J, Pathak H, Pessetto ZY, Koestler DC, Raghavan R, Pei D, Godwin AK. Developing a genetic signature to predict drug response in ovarian cancer. Oncotarget 2018;9:14828-48. [PMID: 29599910 DOI: 10.18632/oncotarget.23663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
569 Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68:240-50. [PMID: 8347478 DOI: 10.1038/bjc.1993.322] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 2.9] [Reference Citation Analysis]
570 Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, Van Waes C. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-?B. Head Neck 2000;22:748-59. [DOI: 10.1002/1097-0347(200012)22:8<748::aid-hed2>3.0.co;2-6] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
571 Moradi H, Ahmad A, Shepherdson D, Vuong NH, Niedbala G, Eapen L, Vanderhyden B, Nyiri B, Murugkar S. Raman micro-spectroscopy applied to treatment resistant and sensitive human ovarian cancer cells. J Biophoton 2017;10:1327-34. [DOI: 10.1002/jbio.201600211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
572 Sherman-baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003;3:377-86. [DOI: 10.1016/s1535-6108(03)00058-8] [Cited by in Crossref: 219] [Cited by in F6Publishing: 121] [Article Influence: 12.2] [Reference Citation Analysis]
573 Kojima S, Matsuki O, Nomura T, Shimura N, Kubodera A, Yamaoka K, Tanooka H, Wakasugi H, Honda Y, Honda S, Sasaki T. Localization of glutathione and induction of glutathione synthesis-related proteins in mouse brain by low doses of γ-rays. Brain Research 1998;808:262-9. [DOI: 10.1016/s0006-8993(98)00832-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
574 Hu J, Friedman E. Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells. Genes Cancer. 2010;1:803-811. [PMID: 21113238 DOI: 10.1177/1947601910377644] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
575 Abe T, Gotoh S, Higashi K. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1999;1445:123-33. [DOI: 10.1016/s0167-4781(99)00036-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
576 Zhang H, Limphong P, Pieper J, Liu Q, Rodesch CK, Christians E, Benjamin IJ. Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J 2012;26:1442-51. [PMID: 22202674 DOI: 10.1096/fj.11-199869] [Cited by in Crossref: 98] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
577 Graham LA, Suryadi J, West TK, Kucera GL, Bierbach U. Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. J Med Chem 2012;55:7817-27. [PMID: 22871158 DOI: 10.1021/jm300879k] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
578 Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther. 2007;7:1369-1378. [PMID: 17944563 DOI: 10.1586/14737140.7.10.1369] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 4.9] [Reference Citation Analysis]
579 Mühlgassner G, Bartel C, Schmid WF, Jakupec MA, Arion VB, Keppler BK. Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. J Inorg Biochem 2012;116:180-7. [PMID: 23037896 DOI: 10.1016/j.jinorgbio.2012.06.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
580 Chern J, Lu C, Fang Z, Chang C, Hua K, Chen Y, Ng CY, Chen YS, Lam Y, Wu S. Affinity-Driven Covalent Modulator of the Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Cascade. Angew Chem Int Ed 2018;57:7040-5. [DOI: 10.1002/anie.201801618] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
581 Shen YA, Liu CS, Chang YH, Chen PH, He CL, Wu HC, Chuang CM. Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer. Cancer Lett 2015;360:39-47. [PMID: 25661733 DOI: 10.1016/j.canlet.2015.01.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
582 Gunay G, Kirit HA, Kamatar A, Baghdasaryan O, Hamsici S, Acar H. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration. Gynecol Oncol 2020;159:563-72. [PMID: 32958270 DOI: 10.1016/j.ygyno.2020.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
583 Perez R. Cellular and molecular determinants of cisplatin resistance. European Journal of Cancer 1998;34:1535-42. [DOI: 10.1016/s0959-8049(98)00227-5] [Cited by in Crossref: 239] [Cited by in F6Publishing: 70] [Article Influence: 10.4] [Reference Citation Analysis]
584 Handel ML, Nguyen LQ, Lehmann TP. Inhibition Of Transcription Factors By Anti-Inflammatory And Anti-Rheumatic Drugs: Can Variability In Response Be Overcome?: Inhibition of transcription factors. Clinical and Experimental Pharmacology and Physiology 2000;27:139-44. [DOI: 10.1046/j.1440-1681.2000.03216.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
585 Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comparative Oncology 2008;6:1-18. [DOI: 10.1111/j.1476-5829.2007.00142.x] [Cited by in Crossref: 234] [Cited by in F6Publishing: 214] [Article Influence: 18.0] [Reference Citation Analysis]
586 Saha A, Jana NR. Detection of Cellular Glutathione and Oxidized Glutathione Using Magnetic–Plasmonic Nanocomposite-Based “Turn-Off” Surface Enhanced Raman Scattering. Anal Chem 2013;85:9221-8. [DOI: 10.1021/ac4019457] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 12.9] [Reference Citation Analysis]
587 Kumari A, Folk WP, Sakamuro D. The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. Genes (Basel) 2017;8:E158. [PMID: 28590415 DOI: 10.3390/genes8060158] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
588 Remacha M, Santos C, Bermejo B, Naranda T, Ballesta J. Stable binding of the eukaryotic acidic phosphoproteins to the ribosome is not an absolute requirement for in vivo protein synthesis. Journal of Biological Chemistry 1992;267:12061-7. [DOI: 10.1016/s0021-9258(19)49806-2] [Cited by in Crossref: 54] [Article Influence: 1.9] [Reference Citation Analysis]
589 Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, Vathipadiekal V, Gunewardena S, Birrer MJ, Godwin AK. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One. 2012;7:e47086. [PMID: 23056589 DOI: 10.1371/journal.pone.0047086] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
590 Volckova E, Dudones LP, Bose RN. HPLC determination of binding of cisplatin to DNA in the presence of biological thiols: implications of dominant platinum-thiol binding to its anticancer action. Pharm Res 2002;19:124-31. [PMID: 11883638 DOI: 10.1023/a:1014268729658] [Cited by in Crossref: 52] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
591 Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004;6:195-206. [PMID: 15153331 DOI: 10.1593/neo.3370] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
592 Kim JK, Kim KD, Lee E, Lim J, Cho H, Yoon HK, Cho M, Baek K, Park YP, Paik S, Choe Y, Lee HG. Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line. Cancer Letters 2004;212:61-70. [DOI: 10.1016/j.canlet.2004.02.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
593 Sawada K, Morishige K, Tahara M, Ikebuchi Y, Kawagishi R, Tasaka K, Murata Y. Lysophosphatidic Acid Induces Focal Adhesion Assembly through Rho/Rho-Associated Kinase Pathway in Human Ovarian Cancer Cells. Gynecologic Oncology 2002;87:252-9. [DOI: 10.1006/gyno.2002.6831] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
594 Lee Y, Kim YJ, Choi YJ, Lee JW, Lee S, Chung HW. Enhancement of cisplatin cytotoxicity by benzyl isothiocyanate in HL-60 cells. Food Chem Toxicol 2012;50:2397-406. [PMID: 22525867 DOI: 10.1016/j.fct.2012.04.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
595 Morales A, Miranda M, Sanchez-Reyes A, Colell A, Biete A, Fernández-Checa JC. Transcriptional regulation of the heavy subunit chain of gamma-glutamylcysteine synthetase by ionizing radiation. FEBS Lett 1998;427:15-20. [PMID: 9613591 DOI: 10.1016/s0014-5793(98)00381-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
596 Cortesi R, Damiani C, Ravani L, Marvelli L, Esposito E, Drechsler M, Pagnoni A, Mariani P, Sforza F, Bergamini P. Lipid-based nanoparticles containing cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as innovative vehicle for Pt complexes: Production, characterization and in vitro studies. Int J Pharm 2015;492:291-300. [PMID: 26187165 DOI: 10.1016/j.ijpharm.2015.07.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
597 Trachootham D, Zhang W, Huang P. Oxidative Stress and Drug Resistance in Cancer. In: Siddik ZH, Mehta K, editors. Drug Resistance in Cancer Cells. New York: Springer US; 2009. pp. 137-75. [DOI: 10.1007/978-0-387-89445-4_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
598 Tanaka-Kagawa T, Kitahara J, Seko Y, Toyoda H, Imura N, Naganuma A. Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase. Biochem Pharmacol 1999;57:545-8. [PMID: 9952318 DOI: 10.1016/s0006-2952(98)00328-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
599 Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol 2012;23:35-42. [PMID: 22355465 DOI: 10.3802/jgo.2012.23.1.35] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
600 Salzillo TC, Mawoneke V, Weygand J, Shetty A, Gumin J, Zacharias NM, Gammon ST, Piwnica-Worms D, Fuller GN, Logothetis CJ, Lang FF, Bhattacharya PK. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells 2021;10:2621. [PMID: 34685601 DOI: 10.3390/cells10102621] [Reference Citation Analysis]
601 Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, Sargent JM. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecol Oncol. 2002;85:298-304. [PMID: 11972391 DOI: 10.1006/gyno.2002.6617] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
602 Barbosa DJ, Capela JP, Silva R, Ferreira LM, Branco PS, Fernandes E, Bastos ML, Carvalho F. "Ecstasy"-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites. Arch Toxicol 2014;88:515-31. [PMID: 24177245 DOI: 10.1007/s00204-013-1147-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
603 Mutlu-Agardan NB, Sarisozen C, Torchilin VP. Cytotoxicity of Novel Redox Sensitive PEG2000-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells. Pharm Res 2020;37:65. [PMID: 32166361 DOI: 10.1007/s11095-020-2759-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]